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Purpose of these guidelines
The Clinical Practice Council of the Society for Vascu-
lar Surgery charged a writing committee with the task of
updating practice guidelines, initally published in 2003, for
surgeons and physicians who are involved in the preopera-
tive, operative, and postoperative care of patients with
abdominal aortic aneurysms (AAA).1 This document
provides recommendations for evaluating the patient,
including risk of aneurysm rupture and associated med-
ical co-morbidities, guidelines for selecting surgical
or endovascular intervention, intraoperative strategies,
perioperative care, long-term follow-up, and treatment
of late complications.
Decision making related to the care of patients with
AAA is complex. Aneurysms present with varying risks of
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2Srupture and patient specific factors influence anticipated
life expectancy, operative risk, and the need to intervene.
Careful attention to the choice of operative strategy, as
influenced by anatomic features of the AAA, along with
optimal treatment of medical co-morbidities is critical to
achieving excellent outcomes. Moreover, appropriate
postoperative patient surveillance and timely interven-
tion in the case of a late complication is necessary to
minimize subsequent aneurysm-related death or mor-
bidity. All of these clinical decisions are determined in an
environment where cost-effectiveness will ultimately dic-
tate the ability to provide optimal care to the largest
possible segment of the population. Currently available
clinical data sets have been reviewed in formulating these
recommendations. However, an important goal of this
document is to clearly identify those areas where further
clinical research is necessary.
Methodology and evidence
A comprehensive review of the available clinical evi-
dence in the literature was conducted in order to generate a
concise set of recommendations. The strength of any given
recommendation and the quality of evidence was scored
based on the GRADE system (Table I).2 When the bene-
fits of an intervention outweighed its risks, or, alternatively,
risks outweighed benefits, a strong recommendation was
noted. However, if benefits and risks were less certain,
either because of low quality evidence or because high
quality evidence suggests benefits and risks are closely
balanced, a weak recommendation was recorded. The
quality of evidence that formed the basis of these recom-
mendations was scored as high, moderate, or low. Not all
randomized controlled trials are alike and limitations may
compromise the quality of their evidence. In addition, if
there is a large magnitude of effect, the quality of evidence
derived from observational studies may be high. Thus,
quality of evidence was scored as high when additional
research is considered very unlikely to change confidence in
the estimate of effect; moderate when further research is
likely to have an important impact in the estimate of effect;
or low when further research is very likely to change the
estimate of the effect.
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History
The medical history is helpful in determining the pa-
tient’s risk of developing an AAA. Even in the absence of
clinical symptoms, knowledge of the risk factors for devel-
oping an AAAmay facilitate early diagnosis. The Aneurysm
Detection and Management Veterans Affairs Cooperative
Study Group (ADAM) trial found a number of factors to be
associated with increased risk for AAA: advanced age,
greater height, coronary artery disease (CAD), atheroscle-
rosis, high cholesterol levels, hypertension, and, in particu-
lar, smoking.3 Indeed, aortic aneurysms occur almost ex-
clusively in the elderly. In a 2001 study, the mean age of
patients undergoing repair for AAA in the United States
was 72 years.4-8 Men outnumber women by a factor of 4 to
6 to 1.4-8 Family members are also at significant risk with
12% to 19% of those undergoing aneurysm repair having a
first-degree relative with an AAA.9-11 In a recent nation-
wide survey conducted in Sweden, the relative risk of
developing AAA for first-degree relatives was approxi-
mately double that of persons without a family history of
AAA.12 Neither the gender of the index person nor the
first-degree relative influenced the risk of AAA. An AAA is
over seven times more likely to develop in a smoker than a
nonsmoker, with the duration of smoking, rather than total
number of cigarettes smoked, being the key variable (Table
II).13 The risk for developing an AAA is lower in women,
African Americans, and diabetic patients.
Risk factors for rupture have also been identified. The
United Kingdom Small Aneurysm trial (UKSAT) reported
103 aneurysm ruptures in 2,257 patients over a period of
seven years, with an annual rupture rate of 2.2%.14 Factors
significantly and independently associated with an in-
Table I. Criteria for strength of a recommendation and
grading quality of evidence






Quality of evidence precludes accurate assessment of risks
and benefits
Grading quality of evidence
High
Additional research is considered very unlikely to change
confidence in the estimate of effect
Moderate
Further research is likely to have an important impact on in
the estimate of effect
Low
Further research is very likely to change the estimate of the
effect
Adapted from Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D,
Hylek EM, Phillips B, et al. Grading strength of recommendations and
quality of evidence in clinical guidelines. Chest 2006;129:174-81.creased risk of rupture included female gender, large initialaneurysm diameter, low forced expiratory volume in one
second (FEV1), current smoking history, and elevated
mean blood pressure.14-16 Women are two to four times
more likely to experience rupture than men.14-17 Aneu-
rysms in transplant patients also appear to have high expan-
sion and rupture rates.18
Prior surgical history is crucial to exclude certain disease
processes, such as appendicitis or cholecystitis, that may
mimic the presentation of a symptomatic aneurysm. In
addition, the nature and extent of previous abdominal
surgery may influence operative approach. When a pulsatile
abdominal mass is discovered in a patient who has previ-
ously undergone open surgical repair (OSR) of an AAA, the
presence of an anastomotic pseudoaneurysm,19 iliac artery
aneurysm,20 or suprarenal aortic aneurysm should be con-
sidered. Likewise, complaints of abdominal or back pain in a
patient with a prior history of endovascular aortic aneurym
repair (EVAR) requires the treating physician to exclude an
endoleak with attendant aneurysm expansion or rupture.21-24
Physical examination
An abdominal aortic aneurysm has been defined as “a
pulsating tumor that presents itself in the left hypochon-
driac or epigastric regions.”25 The abdominal aorta begins
at the level of the diaphragm and the 12th thoracic vertebra
and runs in the retroperitoneal space just anterior to and
slightly to the left of the spine. At approximately the level of
the umbilicus and the fourth lumbar vertebra, the aorta
bifurcates into the right and left common iliac arteries.
Unfortunately, only 30% to 40% of aneurysms are
noted on physical examination with detection dependant
on aneurysm size.26 Aneurysms greater than 5 cm are
Table II. Risk factors for aneurysm development,
expansion, and rupture
Symptom Risk factors




● Family history (male predominance)
AAA expansion ● Advanced age
● Severe cardiac disease
● Previous stroke
● Tobacco use
● Cardiac or renal transplant
AAA rupture ● Female gender
● 2FEV1
● Larger initial AAA diameter
● Higher mean blood pressure
● Current tobacco use (length of time
smoking  amount)
● Cardiac or renal transplant
● Critical wall stress – wall strength
relationship
AAA, Abdominal aortic aneurysm.detected in 76% of patients, whereas aneurysms between 3
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anticipated, detection is limited by truncal obesity.27,28
Althoughmost abdominal aneurysms are supraumbilical, in
some patients, the aorta becomes more tortuous and elon-
gated with age and an aneurysm may appear to be infraum-
bilical or to one side of the abdomen. The common iliac
arteries may also become aneurysmal and palpable in one of
the lower abdominal quadrants. It bears emphasis that
palpation has not been reported to precipitate aortic rup-
ture. An abdominal aneurysm may be present in up to 85%
of patients with a femoral artery aneurysm and in up to 62%
of those with a popliteal aneurysm.29,30 In contrast, pa-
tients with an abdominal aneurysm have a 14% incidence of
either a femoral or a popliteal artery aneurysm.31
Physical examination should include an assessment of femoral and
popliteal arteries in all patients with a suspected abdominal aortic
aneurysm.
Level of recommendation: Strong
Quality of evidence: High
Co-morbid disease
Coronary artery disease (CAD) is the leading cause of
early and late mortality after AAA repair.32 Chronic kidney
disease, chronic obstructive pulmonary disease (COPD),
and diabetes mellitus may also influence morbidity and
mortality. Accordingly, further evaluation is warranted and
optimization of perioperative status beneficial when any of
these conditions are present.
Cardiac disease
Preoperative evaluation of cardiacmorbidity. Several
studies have documented a lower incidence of perioperative
cardiac complications with EVAR than OSR. In review of a
statewide experience between 2000 and 2002, Anderson et
al reported a 3.3% incidence of cardiac complications for
EVAR as compared with 7.8% for OSR in 2002, which was
similar to the events rates in 2001 and 2000.33 Likewise,
Schermerhorn et al34 identified a significantly lower inci-
dence of myocardial infarction (MI) among patients under-
going EVAR as compared with open repair in an analysis of
propensity-score-matched cohorts of Medicare beneficia-
ries treated between 2001 and 2004 (7% vs 9.4%, P 
.001). Similarly, in a small retrospective review of patients
with three or more cardiac risk factors undergoing EVAR
or OSR, the incidence of elevated troponin levels was
significantly lower among those treated by EVAR (13% vs.
47%, P  .001).35 However, not all studies have docu-
mented a reduction cardiac morbidity with EVAR. Nota-
bly, the incidence of cardiac complications was similar for
both EVAR (5.3%) andOSR (5.7%) in the Dutch Random-
ized Endovascular Aneurysm Management (DREAM)
trial.36 In summary, while elective open AAA repair can
generally be considered to carry a higher risk for a periop-
erative cardiovascular event, EVAR should be considered a
procedure that is associated with intermediate to high
cardiac risk in the range of 3% to 7%.Regardless of the nature of repair, a substantial portion
of patients with AAA have underlying CAD and postoper-
ative MI carries with it a substantially increased risk of
death, as well as a high risk for later cardiovascular events
and death.37,38 Thus, it is critical to minimize the risk of
cardiac morbidity during the course of OSR or EVAR for
AAA. Guidelines, endorsed by the Society for Vascular
Surgery, have been recently updated for preoperative car-
diac evaluation of patients undergoing noncardiac vascular
surgery.39 Past guidelines have proven safe and effective in
reducing unnecessary resource utilization.40-42
The first step, prior to planned aneurysm repair, is to
determine whether an active cardiac condition exists, such
Table III. Preoperative cardiac evaluation for patients
undergoing aneurysm repair
1. Is there an active cardiac
condition?
● Unstable coronary syndrome
● Unstable or severe angina
● Recent MI (1 month)
● Decompensated CHF
● Significant arrhythmias
● Severe valvular disease





2. Does the patient have
good functional capacity
without symptoms?
● MET 4 (see Table IV)
Clinical risk factors:
● Mild angina pectoris
● Prior MI
● Compensated or prior CHF
● Diabetes mellitus
● Renal insufficiency
May proceed with aneurysm
repair. In patients with known
cardiovascular disease or at
least one clinical risk factor,
beta blockade is appropriate.
3. Is functional capacity
poor or unknown?
● MET 4 (see Table IV)
Clinical risk factors:
● Mild angina pectoris
● Prior MI
● Compensated or prior CHF
● Diabetes mellitus
● Renal insufficiency
In patients with three or more
clinical risk factors, preoperative
non-invasive testing is
appropriate if it will change
management.
CHF, Congestive heart failure; MET, metabolic equivalent unit; MI, myo-
cardial infarction.
Adapted from Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof E,
Fleischmann KE, et al. ACC/AHA 2007 Guidelines on perioperative car-
diovascular evaluation and care for noncardiac surgery: executive summary.
Circulation 2007;116:1971-96.as an unstable coronary syndrome (unstable or severe an-
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(new onset, worsening, or New York Heart Association
[NYHA] Class IV), significant arrhythmia (atrioventricular
[AV] block, poorly controlled atrial fibrillation, new onset
ventricular tachycardia), or severe valvular heart disease
(symptomatic, aortic valve area  1 cm2 or pressure gradi-
ent 40 mm Hg) (Table III). These conditions represent
major clinical risks for postoperative MI or cardiovascular
related death and mandate intensive management prior to
aneurysm repair. In these cases, patients may be referred for
coronary angiography to assess further therapeutic options.
Depending on the results of the test and the risk of delaying
repair, it may be appropriate to proceed to planned surgical
or endovascular treatment with maximal medical therapy.
In the absence of an active cardiac condition, further
non-invasive testing is only indicated if it will change man-
agement. For an otherwise elective repair, both the pa-
tient’s functional capacity and the presence of clinical risk
factors will dictate the need for further testing. The func-
tional capacity can be estimated from a patient’s ability to
perform various activities (Table IV). Asymptomatic pa-
tients capable of a moderate or high activity level (meta-
bolic equivalent unit [MET] 4), such as climbing stairs or
a short run, generally do not benefit from further testing.
Those who cannot achieve these levels of activity or in
whom activity level is unknown may benefit from non-
invasive stress testing, if additional clinical risk factors exist.
Lee et al43 have derived and validated a Revised Cardiac
Risk Index for stable patients, without an active cardiac
condition. Five independent clinical risk factors were iden-
Table IV. Estimated energy required for various
activities
Activity level Examples of activity level
Poor (1-3 METs) Eating, walking at 2-3 miles per hour,
getting dressed, light housework
(washing dishes)
Moderate (4-7 METs) Climbing a flight of stairs or walking up
a hill, running a short distance, heavy
housework (scrubbing floors or
moving furniture)
Good (7-10 METs) Doubles tennis, calisthenics without
weights, golfing without cart
Excellent (10 METs) Strenuous sports such as football,
basketball, singles tennis, karate,
jogging 10 minute mile or greater,
chopping wood
MET,Metabolic equivalent unit (1 MET 3.5 mL  kg1 min1 oxygen
uptake).
Adapted from The Duke Activity Status Index (Hlatky MA, Boineau RE,
Higginbotham MB, Lee KL, Mark DB, Califf RM, et al. A brief self-
administered questionnaire to determine functional capacity (the Duke
Activity Status Index). Am J Cardiol 1989;64:651-4. and Nelson CL,
Herndon JE, Mark DB, Pryor DB, Califf RM, Hlatky MA. Relation of
clinical and angiographic factors to functional capacity as measured by the
Duke Activity Status Index. Am J Cardiol 1991;68:973-5.).tified including heart disease (history of MI, positive tread-mill test, use of nitroglycerin, angina, or electrocardiogram
[ECG] with abnormal Q waves); congestive heart failure
(history of heart failure, pulmonary edema, paroxysmal
nocturnal dyspnea, peripheral edema, bilateral rales, S3, or
chest radiograph with pulmonary vascular redistribution);
cerebral vascular disease (history of transient ischemic at-
tack or stroke); diabetes mellitus; and renal insufficiency
(creatinine  2 mg/dL). The presence of an increasing
number of risk factors correlates with an increased risk of a
postoperative event and patients who display three or more
risk factors andhave anunknownor low activity level (MET
4) may benefit from stress testing, if it will change
management. Otherwise, all patients should undergo a
12-lead ECG within one month of planned repair. Trans-
thoracic echocardiography (TTE) may be of value in pa-
tients with dyspnea of unknown origin or worsening dys-
pnea and a history of heart failure, if TTE has not been
performed within the past year. However, it should be
noted that resting left ventricular function is not a consis-
tent predictor of postoperative MI or death.
Patients with active cardiac conditions (eg, unstable angina,
decompensated heart failure, severe valcular disease, significant
arrythmia) should be evaluated and treated per American College
of Cardiology (ACC)/American Heart Association (AHA)
guidelines before EVAR or OSR.
Level of recommendation: Strong
Quality of evidence: Moderate
Noninvasive stress testing should be considered for patients with a
history of three or more clinical risk factor factor (ie, coronary
artery disease [CAD], congestive heart failure [CHF],
cerebrovascular accident [CVA], diabetes mellitus [DM], chronic
renal insufficiency [CRI]) and an unknown or poor functional
capacity (MET 4) who are undergoing aneurysm repair, if it will
change management.
Level of recommendation: Strong
Quality of evidence: Moderate
A preoperative resting 12-lead ECG is recommended for all
patients undergoing endovascular or open aneurysm repair within
30 days of planned treatment.
Level of recommendation: Strong
Quality of evidence: High
Preoperative echocardiography is recommended for patients
undergoing aneurysm repair with dyspnea or heart failure.
Level of recommendation: Strong
Quality of evidence: High
Routine coronary revascularization by coronary artery
bypass grafting (CABG) or percutaneous transluminal cor-
onary angioplasty (PTCA) prior to elective vascular surgery
in patients with stable cardiac symptoms does not appear to
significantly alter the risk of postoperative MI or death or
long-term outcome. In the Coronary Artery Revasculariza-
tion Prophylaxis (CARP) trial, 510 patients with significant
coronary artery stenosis scheduled for vascular operations
were randomized to PTCA or CABG or no coronary
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disease, severe aortic stenosis, or an ejection fraction of less
than 0.20 were excluded. Both short-term risk and long-term
outcome were not changed by coronary intervention. Similar
findings have been reported by other randomized stud-
ies.45,46 Patients with stable cardiac disease and established
risk factors remain at risk, whether or not coronary revascular-
ization is performed. Nonetheless, it bears emphasis that cor-
onary revascularization is indicated for those patients with
acute ST elevation MI, unstable angina, or stable angina with
left main coronary artery or three-vessel disease, as well as
those patients with two-vessel disease that includes the proxi-
mal left anterior descending artery, and either ischemia on
non-invasive testing or an ejection fraction of less than 0.50.
In summary, percutaneous or surgical intervention for
coronary artery disease prior to aortic surgery should be con-
sistent with established guidelines.47 If a patient requires
PTCA, it may be reasonable for patients to wait at least two
weeks and, preferably, four to six weeks after PTCA before
undergoing aneurysm repair.39 If a drug eluting stent is uti-
lized, it may be reasonable to defer surgery for 12 months if
rupture risk is not high. If this is not possible, EVAR is
preferred as thienopyridine therapy can be continued during
the perioperative period. If OSR is required, the thienopyri-
dine should be discontinued 10 days preoperatively, aspirin
continued, and the thienopyridine restarted as soon as possi-
ble after surgery.48 Simultaneous aneurysm repair and CABG
has been evaluated, and there are some data to support its use
in select symptomatic patients with critical CAD.49,50
Coronary revascularization is recommended prior to aneurysm
repair in patients with acute ST elevation MI, unstable angina, or
stable angina with left main coronary artery or three-vessel disease.
Level of recommendation: Strong
Quality of evidence: High
Coronary revascularization is recommended prior to aneurysm repair
in patients with stable angina with two-vessel disease that includes the
proximal left anterior descending artery, and either ischemia on non-
invasive testing or an ejection fraction of less than 0.5.
Level of recommendation: Strong
Quality of evidence: High
In patients who may need AAA repair in the subsequent 12 months
and in whom coronary revascularization with percutaneous coronary
intervention (PCI) is appropriate, a strategy of balloon angioplasty or
bare-metal stent placement followed by four to six weeks of dual-
antiplatelet therapy is suggested.
Level of recommendation: Weak
Quality of evidence: Moderate
It is suggested to defer elective open AAA repair for four to six
weeks after bare-metal coronary stent implantation or coronary
artery bypass grafting or for 12 months after drug-eluting coronary
stent implantation, if rupture risk is not high.
Level of recommendation: Weak
Quality of evidence: LowIn patients who have received drug-eluting coronary stents and who
must undergo open AAA repair, it is suggested to discontinue
thienopyridine therapy 10 days preoperatively, continue aspirin,
and restart the thienopyridine as soon as possible after surgery.
Level of recommendation: Weak
Quality of evidence: Low
Perioperative medical management of coronary ar-
tery disease. Although animal studies have suggested that
beta blockade protects against aneurysm expansion and
rupture, the evidence in clinical trials has generally not
supported this view.51-56 However, in patients with known
cardiovascular disease or at least one clinical risk factor,
perioperative heart rate control with beta blockade appears
appropriate. Several randomized, controlled trials have
demonstrated that perioperative beta blockade in high-risk
patients reduce cardiac morbidity and death.57-59 Beta
blockers should be started days to weeks before elective
surgery and accumulating evidence suggests that heart rate
control less than 65 beats per minute should be targe-
ted.45,60 Additionally, data suggest that long-acting beta
blockade may be superior to short-acting beta blockade.61
Recent clinical data also supports the notion that st-
atins,62-64 alpha-2 agonists for perioperative control of hyper-
tension,65,66 and calcium channel blockers67 reduce periop-
erative cardiac morbidity and death. Aspirin is beneficial in
reducing risks associated with CAD68 and most surgeons
continue aspirin during the perioperative period.69Coumadin
should be discontinued five to seven days prior to abdominal
aortic aneurysm repair. Use of either intravenous heparin or
lowmolecular weight heparin to bridge patients undergoing a
major aortic operation has been reviewed elsewhere.70,71
Beta blockers should be continuedin patients undergoing aneurysm
surgery who are currently receiving beta blockers to treat angina,
symptomatic arrhythmias, or hypertension.
Level of recommendation: Strong
Quality of evidence: High
Beta blockade is recommended for patients undergoing aneurysm
repair in whom preoperative assessment identifies CAD or who are
at high cardiac risk due to the presence of one or more clinical risk
factors (i.e. CAD, CHF, CVA, DM, CRI).
Level of recommendation: Strong
Quality of evidence: Moderate
Pulmonary disease. Between 7% and 11% of patients
with chronic obstructive pulmonary disease (COPD) have
an aneurysm.14 In a study of 4,404men between 65 and 73
years of age, the prevalence of aortic aneurysms was 4.2%,
but increased to 7.7% amongmenwith COPD.72 Although
an accelerated rate of aneurysm expansion has been ob-
served in patients treated with corticosteroids, the associa-
tion between aneurysm and COPD has been largely attrib-
uted to accelerated elastin degradation caused by tobacco
use. Indeed, smoking remains the most significant risk
factor for aneurysm formation and has been implicated in
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ture.75 Current smokers are over seven times more likely to
have an aneurysm than nonsmokers with the duration of
smoking being the most important variable.13 Each year of
smoking increases the relative risk of developing an aneu-
rysm by 4%. After cessation of smoking, there is a slow
decline in the risk of aneurysm occurrence.
Several studies have reported that COPD is an inde-
pendent predictor of operative mortality after AAA re-
pair.4,76,77 However, a study of Veterans Administration
patients found no significant correlation between the pres-
ence of COPD and increased operative mortality, though
morbidity was notably higher.78 Upchurch et al79 have also
demonstrated that abnormal preoperative pulmonary func-
tion tests and arterial blood gas values were not predictive
of a poor outcome after aneurysm repair. However, failure
to optimize COPD management was associated with in-
creased morbidity and mortality.
Given these considerations, room air arterial blood gases
and pulmonary function tests should be considered to assess
the extent of COPD. If COPD is severe, formal pulmonary
consultation is recommended for prediction of short- and
long-term prognosis and optimization of medical therapy. In
general, smoking cessation for at least two weeks prior to
aneurysm repair can be beneficial and administration of pul-
monary bronchodilators for at least two weeks prior to aneu-
rysm repair is recommended for patients with a history of
symptomatic COPD or abnormal pulmonary function stud-
ies. Finally, the diagnosis of an aneurysm can be a strong
motivator for smoking cessation.80 Numerous studies and
several Cochrane reviews have assessed the efficacy of smoking
cessation strategies.Nicotine replacement,81 nortriptyline and
bupropion,82 and the combination of in-patient counseling
coupled with at least one month of outpatient follow-up have
proven beneficial for smoking cessation.80
Preoperative pulmonary function studies, including room air
arterial blood gases, are suggested for patients with a history of
symptomatic COPD, long-standing tobacco use, or inability to
climb one flight of stairs.
Level of recommendation: Weak
Quality of evidence: Low
Smoking cessation for at least two weeks prior to aneurysm repair
can be beneficial.
Level of recommendation: Strong
Quality of evidence: Low
Administration of pulmonary bronchodilators for at least two weeks
prior to aneurysm repair is recommended for patients with a history
of symptomatic COPD or abnormal pulmonary function studies.
Level of recommendation: Strong
Quality of evidence: Low
Renal impairment. Preoperative renal insufficiency is
known to be a risk factor for a poor outcome after aneurysm
repair76,78,79 and should be evaluated and, if possible,corrected. In a review of 8,125 intact abdominal aneurysm
repairs in the state ofMichigan, the presence of renal failure
was associated with a 41% mortality as compared with 6%
for those patients without significant renal disease.83 Like-
wise, severe renal dysfunction (creatinine  2.5 mg/dL)
lead to increased mortality and morbidity among 342 pa-
tients undergoing EVAR with increased length of stay,
intensive care unit (ICU) admission, and congestive heart
failure.84 A recent review has also observed that while many
patients with renal insufficiency will have only a transient
deterioration in renal function, mortality and morbidity,
including the need for more intensive postoperative organ
system support, appear to be increased.85
Surprisingly, there is little data regarding the specifics of
management in patients undergoing AAA repair with
chronic renal insufficiency (CRI) andwhethermanagement
should be guided by serum creatinine, creatinine clearance,
or glomerular filtration rate. In the perioperative period,
relative or absolute changes in blood volume can cause
renal injury. Thus, preoperative hydration is recommended
to ensure euvolemia, especially for those patients with renal
insufficiency. However, the optimal type, route, volume,
and timing of hydration are not well defined. Likewise,
given the ability of angiotensin-converting enzyme inhibi-
tors and angiotensin receptor antagonists to induce efferent
arteriole vasodilatation, these medications should be held
the morning of surgery and restarted only after the patient
is euvolemic.86-88 Although administration of antioxidants,
such as mannitol, during OSR has been advocated as reno-
protective agents, a recent meta-analysis did not identify a
significant benefit with mannitol use alone.89 However, a
small, prospective randomized trial has suggested that peri-
operative administration of multiple antioxidants (allopuri-
nol, vitamin E, ascorbic acid, N-acetylcysteine, and manni-
tol) may lead to a beneficial increase in creatinine clearance
after OSR.90 Fenoldopammesylate, a dopamine-1 receptor
agonist, has also been studied as a renoprotective agent in
both surgical and critically ill patients at risk for acute renal
insufficiency. A recent meta-analysis of 16 randomized
studies found that fenoldopam reduced the risk of acute
kidney injury, renal replacement therapy, and in-hospital
death.91Many of the beneficial trials administered fenoldo-
pam at 0.1 g/kg/min beginning at the initiation of
surgery. Gilbert et al92 and Halpenny et al93 have noted a
renoprotective effect during and after infrarenal aortic
cross-clamping among patients with normal or mild renal
dysfunction.
Contrast-induced nephropathy (CIN) has been de-
fined as a 25% elevation in serum creatinine or an abso-
lute increase of 0.5 mg/dL (44 mol/L) occurring two
to seven days after contrast administration. Patients with
a history of renal disease, diabetes, CHF, ejection frac-
tion (EF) 40%, hypertension, anemia, advanced age,
proteinuria, renal surgery, and gout are at increased risk
for CIN. Multiple investigations and meta-analyses have
sought to determine if prophylactic intravenous hydra-
tion, N-acetylcysteine (Mucomyst), or other agents can
reduce the risk of CIN. Pre- and post procedure hydra-
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linize renal tubular fluid and minimize tubular damage,
appears to be beneficial.94 However, whether all patients
benefit equally from this treatment, as well as the optimal
type, route, volume, and timing of hydration are not well
defined. Fenoldapam, dopamine, theophylline, or cal-
cium channel blockers do not appear to be beneficial in
preventing CIN. The benefit of N-acetylcysteine in re-
ducing CIN remains uncertain95 and in a recent trial did
not reduce CIN in patients undergoing EVAR.96 None-
theless, its use continues to be advocated for patients at
increased risk of CIN.
Contrast agents with an osmolality of greater than 780
mOsm/kg display increased nephrotoxicity. Additional ne-
phroprotection through further reduction in radiocontrast
osmolality was suggested by a study comparing iohexol
(Omnipaque, a low-osmolar agent; 600-800 mOsm/kg)
with iodixanol (Visipaque, an iso-osmolar agent; 290
mOsm/kg).97 However, the rates of CIN for iopamidol
(Isovue-370, 796 mOsm/kg, non-ionic) are similar to
iodixanol, which suggests that other physiochemical prop-
erties, apart from omolarity, are important determinants of
CIN.98 Likewise, several randomized trials of ionic and
nonionic contrast agents have demonstrated no difference
in CIN.95
In summary, patients at increased risk for CIN should
receive intravenous hydration prior to (normal saline 1
ml/kg/h for six to 12 hours or D5W/sodium bicarbonate
154meq/L, 3 mL/kg for one hour) and after (normal saline
1 ml/kg/h for six to 12 hours or D5W/sodium bicarbonate
154 meq/L, 1 mL/kg for six hours) EVAR. Fluid overload
and metabolic alkalosis should be monitored. Periprocedural
N-acetylcysteine and ascorbic acid may be of benefit.95 Mini-
mizing the volume of low-osmolar or iso-osmolar contrast
agents administered during EVAR is recommended. Use of
CO2 gas, as an alternate imaging agent may be considered.99
Gadolinium-based contrast agents carry an increased risk of
nephrogenic systemic fibrosis among patients with severe re-
nal insufficiency.
Angiotensin-converting enzyme inhibitors and angiotensin receptor
antagonists should be held the morning of surgery and restarted
after the patient is euvolemic.
Level of recommendation: Strong
Quality of evidence: Moderate
Preoperative hydration is recommended for patients with renal
insufficiency prior to aneurysm repair.
Level of recommendation: Strong
Quality of evidence: Moderate
Intraoperative diuresis using fuorosemide or mannitol is probably
not beneficial in reducing the risk of postoperative renal
insufficiency after aneurysm repair.
Level of recommendation: Strong
Quality of evidence: HighPre- and post procedure hydration with normal saline or 5%
dextrose/sodium bicarbonate is recommended for patients at
increased risk of contrast induced nephropathy.
Level of recommendation: Strong
Quality of evidence: Moderate
Diabetes mellitus. Whether diabetes mellitus is truly
an independent risk factor for morbidity or mortality after
aortic surgery is controversial. Several small studies have
shown that the risk of perioperative complications, but not
death, is greater among diabetic patients.100-102 A recent
report demonstrated that diabetes did increase the risk of
death and cardiovascular complications in Veterans Admin-
istration patients undergoing major vascular proce-
dures.103 However, subgroup analysis failed to demon-
strate that diabetic patients undergoing OSR were at
increased risk. In contrast, Leurs et al104 investigated the
influence of diabetes on outcome after EVAR among 6,017
patients enrolled in the European Collaborators on Stent
Graft Techniques for Abdominal Aortic Aneurysm Repair
(EUROSTAR) registry, of whom 731 (12%) had diabetes.
A significantly higher risk of device-related complications
was observed in diabetic patients (8% vs 6%, P .049; odds
ratio [OR]: 1.35). Likewise, early mortality was signifi-
cantly higher in the diabetic population (13% vs 10%, P 
.039; OR: 1.27). Insulin-controlled type 2 diabetic patients
had significantly lower rates of endoleaks and secondary
interventions than diet-controlled type 2 diabetics and
nondiabetic patients. Survival at 48 months was similar
among diabetic and non-diabetic patients. In summary,
diabetes likely identifies patients with a variety of co-
morbidities that increase the risk of morbidity and mortal-
ity. Nonetheless, conventional glucose control during the
perioperative period, with a target of 180 mg or less per
deciliter ( 10.0 mmol/L), is recommended.
Hematologic disorders. Elevated levels of homocys-
teine (OR: 7.8;P .0001), plasminogen activator inhibitor-1
(PAI-1) (OR: 3.2; P  .0001), and lipoprotein (a) (OR:
2.4; P  .0001) have been observed among patients with
aortic aneurysms when compared to age and gender
matched controls.105 The role of these factors in aneurysm
formation is unknown and the benefit of treatment in
reducing aneurysm expansion uncertain. Anticardiolipin
antibodies (ACA), MTHFR C677T polymorphism, pro-
thrombin gene G20210A variant, and Factor V Leiden
mutation have not been found more frequently in patients
presenting with aortic aneurysms.
A number of studies have documented that even in the
elective setting, anemia or a low hemoglobin level is asso-
ciated with increased mortality following open AAA re-
pair.79,106 Ho and colleagues106 documented that a hemo-
globin level of less than 10.5 g/dL was an independent
determinant of blood loss. A hematocrit less than 28% has
also been associated with an increased incidence of postop-
erative MI in patients undergoing vascular surgery.107
Therefore, we recommend perioperative blood transfusion
if the preoperative hematocrit is less than 28%.
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should not be performed unless the platelet count is greater
than 20,000 to 40,000 platelets/L.While the question of
what platelet count specifically is too low to perform elec-
tive AAA repair and the impact this might have onmortality
has not been addressed directly, it is recognized that the
presence of an AAA does impact both platelet count as well
as platelet function. In a prospective study comparing 105
patients with AAAs with 32 patients with symptomatic
carotid disease, Milne and coauthors documented that a
combination of a low platelet count and high glycocalicin
levels suggests that there is increased platelet destruction in
patients with AAAs, most likely due to activation within the
aneurysm sac.108 While not specifically addressing the
impact on mortality, Ho and others did document in 129
patients undergoing elective AAA repair that a platelet
count of 130,000 platelets/L or less was associated
with increased risk of bleeding.106 In addition, it is well
recognized that following aortic clamping, platelet se-
questration and thrombocytopenia occur in the early
postoperative period. Patients subsequently develop hy-
perfibrinogenaemia and thrombocytosis, which may per-
sist for several weeks.109 Finally, Matsumura and col-
leagues suggested that a lower preoperative platelet
count was an independent predictor of two-year mortal-
ity among patients undergoing OSR and EVAR (P 
.012).110 Thus, further hematologic assessment is rec-
ommended if the preoperative platelet count is less than
130,000 platelets/L.
Perioperative blood transfusion is recommended if the preoperative
hematocrit is 28%.
Level of recommendation: Weak
Quality of evidence: Low
Further hematologic assessment is recommended if the preoperative
platelet count is less than 130,000 platelets/L.
Level of recommendation: Weak
Quality of evidence: Low
Circulating biomarkers for the presence and pro-
gression of aortic aneurysms. The identification of cir-
culating biomarkers that indicate the presence or en-
largement of AAA remains an area of active investigation.
Such markers may assist in identifying new targets for
pharmacotherapy and could be used for both diagnosis
and monitoring response to therapy. Among a large
number of biomarkers evaluated to date, fibrinogen,
D-dimer, and IL-6 have been consistently associated
with the presence of AAA in multiple cross-sectional case
controlled studies.111 However, none of these biomark-
ers have appropriate sensitivity or specificity to be used as
a diagnostic test. A reliable marker of AAA progression
has yet to be identified.
Genetic markers identifying risk of aortic aneu-
rysm. Genetic abnormalities associated with AAA, in-
clude Ehlers-Danlos type IV (COL3A1), an autosomaldominant defect in the type-III collagen synthesis.112 Of
interest, while mutations in the type I collagen, alpha I
(COL1A1) gene leads to osteogenesis imperfecta there is
no evidence indicating these mutations nor those of the
elastin gene are responsible for AAA.113 Marfan syn-
drome is autosomal dominant disorder with variable
penetrance caused by mutations in the fibrillin 1. The
most common vascular complication includes aneurys-
mal degeneration and dissection of the ascending aorta.
While arteriomegaly is common, isolated AAA that is
unrelated to a prior aortic dissection, is uncommonly
associated with Marfan syndrome.113 Definitive data is
lacking regarding the contribution of genetic mutations
of other structural components of the connective tissue
or genetically related alterations in post-translational
protein modification, protein metabolism, or proteases
and their inhibitors to familial AAA.
In a related area, population screening for single nucle-
otide polymorphisms (SNPs) to identify patients at risk for
AAA have generated conflicting results. Although a num-
ber of genetic variants have been identified, few, if any, of
these findings have been reproduced in more than one
independent research group. A recent large study has
suggested that a common sequence variant on 9p21,
rs10757278-G, is associated with a 31% increased risk of
abdominal aortic aneurysm.114 Genome wide screening
may serve to identify additional genetic markers for disease,
which may further assist in targeting early ultrasound
screening for populations at greatest risk.
Aneurysm imaging
Modalities for aneurysm imaging. Among asymp-
tomatic patients, ultrasound detects the presence of an
abdominal aortic aneurysm accurately, reproducibly, and at
low cost. Sensitivity and specificity approach 100%, but in
1% to 3% of patients, the aorta cannot be visualized due to
bowel gas or obesity.115,116 Ultrasound is ideal for screen-
ing,117 but is imprecise in measuring aneurysm size,118-120
which is an important component of prognosis121 and in
the determination of aneurysm growth rate.122 A growth
rate of  0.7 cm per six months or 1 cm per year has been
suggested as a threshold for proceeding to surgery irrespec-
tive of aneurysm size.51,123,124 However, it should be
noted that the presumption that growth rate influences
rupture risk independent of aneurysm size has not been
confirmed by population based studies.125
CT is more reproducible than ultrasound, with more
than 90% of re-measurements within 2 mm of the initial
reading.126 However, aneurysms measured by standard
axial CT imaging are generally more than 2 mm larger in
diameter than those measured by ultrasound. This likely
reflects that the cross-section of the aorta obtained by
axial CT imaging is not in the transverse plane and
presumably yields an overestimate of aneurysm size.
Overall, the advantages of portability and decreased
expense have made ultrasound the preferred diagnostic
technique for both aneurysm screening and surveil-
lance.126-128 Nevertheless, CT imaging remains the pri-
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of this technique to determine the extent and morphol-
ogy of the aneurysm, as well as the presence of accessory
or anomalous renal arteries and coexistent occlusive
disease. It bears noting that plain abdominal films and
aortography have low sensitivity in the detection of AAA.
In the latter instance, the amount of aortic dilatation may
be obscured by the presence of thrombus.
Ultrasound is readily available in most emergency
departments and used with increasing facility by the
emergency physicians to exclude a variety of causes of
abdominal pain including urinary retention, pancreatitis,
cholecystitis, and hydronephrosis, among other disor-
ders. Several studies have reported high sensitivity (94%
to 100%) and specificity (98% to 100%) in detecting
non-ruptured aneurysms by ultrasound.129,130 How-
ever, significant portions of the aorta may not be visual-
ized in non-fasted patients and aortic rupture is not easily
detected and up to half of aneurysm ruptures may be
missed.128,131 CT imaging for detection of symptomatic
AAA has been found to have a sensitivity and specificity
of 90% and 91%, respectively.132 However, in a study of
653 patients with suspected AAA rupture, CT imaging
had a sensitivity of 79% and a specificity of 77%. Only
40% of CT scans were performed with contrast, which
presumably contributed to the diminished sensitivity and
specificity noted in this report.133
Image derived criteria to predict risk of AAA rup-
ture. The maximum AAA diameter remains the most
widespread criterion to predict risk of AAA rupture. The
adoption of maximum diameter as a measure of rupture
risk was based, in part, on a retrospective review by
Darling et al134 of 24,000 consecutive, non-specific au-
topsies performed over a 23-year period, which identi-
fied 473 non-resected AAA, of which 118 were ruptured.
Approximately 40% of AAA greater than 5 cm in diame-
ter ruptured. Nonetheless, this same report highlights
the limitation of aneurysm diameter as a predictor of
rupture risk since 40% of AAA between 7 cm and 10 cm
had not ruptured, while nearly 13% of patients with
aneurysms smaller than 5 cm had ruptured. Thus, a
variety of alternate parameters have been proposed as
more sensitve predictors of rupture risk including AAA
expansion rate15,123,135,136 increase in intraluminal
thrombus thickness,137 wall stiffness,138 wall tension,139
and peak AAA wall stress.140-142
Most recent reports have emphasized the potential
significance of aortic wall stress as a predictor of AAA
rupture. Hall et al139 suggested that a critical aortic wall
stress exists above which rupture is imminent and that
this stress can be predicted by the Law of Laplace and
maximum AAA diameter. However, others140-145 have
demonstrated that stresses are highly dependent on AAA
shape and cannot be adequately described by the Law of
Laplace. Using patient-specific finite element (FE) sim-
ulations, Fillinger et al140,141 have observed that peak
wall stress for ruptured or symptomatic AAA were signif-
icantly greater than those electively repaired (46.8  4.5N/cm2 vs 38.1  1.3 N/cm2).142 Recently, Klein-
streuer and Li146 have proposed a patient-specific “se-
verity parameter’’ to estimate the risk of AAA rupture.
This time-dependent parameter incorporates features of
AAA geometry including size, shape, expansion rate, and
thrombus, as well as diastolic pressure, peak AAA wall
stress, and stiffness change. As an enlarging AAA is
accompanied both by an increase in wall stress and a
decrease in wall strength, recent efforts have also been
directed to accurately map the pointwise distribution of
AAA wall stress and strength as a more accurate determi-
nant of rupture risk.147 Further validation of these tools
will be required before they can be applied with confi-
dence in clinical practice.
Recommendations for aneurysm screening. Aneu-
rysm screening efforts have been motivated by a desire to
reduce AAA-related mortality and to prolong life expect-
ancy. The incidence of AAA is less than one per 1000 for
those adults younger than 60 years, peaks to approximately
seven per 1000 among those in their mid 60s, and then
decreases and remains at approximately three per 1000. It is
estimated that 5% to 10% of older adult men have an AAA,
but the majority of AAAs are small.148 The prevalence of
AAA is approximately six times lower in women than in
men.149 Overall, the probability of AAA in the general
population is very low but, as noted earlier, is increased
when certain risk factors are present. These include increas-
ing age, male gender, white race, smoking, family history,
history of other vascular aneurysms, hypertension, athero-
sclerotic diseases, including coronary artery, peripheral ar-
terial, and cerebrovascular disease, and hypercholesterol-
emia.51,150-159 The largest AAA screening program in the
United States was conducted in asymptomatic veterans
between 50 and 79 years old.158 The prevalence of AAA in
the most important risk groups is summarized in Table V.
Two-thirds of aneurysms detected by ultrasound were
found to be 4.0 cm. Of note, the prevalence of AAA is
much higher among patients in the health care setting than
in the general population. In one study, 9% of men aged 60
to 75 years with hypertension or coronary artery disease had
Table V. Prevalence of small and medium AAAs among
73,451 US military veterans between 50 to 79 years†





White Male Smoker 5.9 1.9
Nonsmoker 1.9 0.4
White Female Smoker 1.9 0.3
Nonsmoker 0.6 0
Black Male Smoker 3.2 0.8
Nonsmoker 1.4 0.1
Adapted from Table II in Lederle FA, Johnson GR, Wilson SE, Chute EP,
Littooy FN, BandykD, et al. Prevalence and associations of abdominal aortic
aneurysm detected through screening. Aneurysm Detection and Manage-
ment (ADAM) Veterans Affairs Cooperative Study Group. Ann Intern Med
1997;126:441-9.
†The prevalence of AAAs among black females was not reported.an AAA 3.5 cm.28
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men and 9,342 women between the ages of 65 and 79 years
have provided evidence that ultrasound screening is effective
in reducing AAA-related mortality, but not all-cause mort-
ality.149,160-164 A recent follow-up report of the MASS study
confirms that mortality benefits are maintained at seven years
and cost-effectivness is well below accepted thresholds for
interventions. Significantly, a trend toward a reduction in
all-cause mortality was observed.165 Screening of AAA in
women has beenmore controversial. Given the small number
of women among these four trials, a significant decrease in
mortality from AAA (OR: 1.99; 95% confidence interval [CI]
0.36 to 10.88) or incidence of rupture (OR: 1.49; 95% CI
0.25 to 8.94) in women could not be identified.166However,
others have claimed that screening of women for AAA is
cost-effective.167 Although the prevalence of AAA in women
is lower than in men, rupture rate and life expectancy are
higher. Studies have demonstrated that re-screening patients
for AAA yields very few positive results, which suggests that a
single ultrasound scan would be sufficient to screen patients
65 years of age or older.168,169
Despite these data, the availability of limited health
care resources has motivated efforts to identify risk fac-
tors to be used in selective screening of high-risk groups.
For example, a Canadian hospital-based case-control
study found that if AAA risk was based on age, smoking,
blood pressure, body mass index, history of heart disease,
and serum high-density lipoprotein, 80% of AAA cases
could be identified by studying 17% of patients.170 Like-
wise, Akkersdijk et al have suggested that use of a risk
factor score could identity 94% of men with AAA by
screening approximately half of the male population.171
Others have concluded, however, that while selective
screening is feasible, approximately 25% of clinically
significant AAAs may be missed.172
We recommend one-time ultrasound screening for
AAA for all men at or older than age 65, or as early as age 55
for those with a family history of AAA. Ultrasound screen-
ing should be performed for women at or older than age 65
who have smoked or have a family history. This is in
contrast to the US Preventive Services Task Force rec-
ommendation for one-time screening by ultrasonogra-
phy for men aged 65 to 75, if a history of smoking
exists.173,174 Currently, Medicare offers an ultrasound
screening benefit to men who have smoked at least 100
cigarettes during their life, and men and women with a
family history of AAA as part of their Welcome to Medi-
care Physical Exam. This benefit became law on February
8, 2006, as the Screening Abdominal Aortic Aneurysms
Very Efficiently (SAAAVE) Act.
One-time ultrasound screening for AAA is recommended for all
men at or older than 65 years. Screening men as early as 55 years is
appropriate for those with a family history of AAA.
Level of recommendation: Strong
Quality of evidence: HighOne-time ultrasound screening for AAA is recommended for all
women at or older than 65 years with a family history of AAA or
who have smoked.
Level of recommendation: Strong
Quality of evidence: Moderate
Re-screening patients for AAA is not recommended if an initial
ultrasound scan performed on patients 65 years of age or older
demonstrates an aortic diameter of 2.6 cm.
Level of recommendation: Strong
Quality of evidence: Moderate
Recommendations for aneurysm surveillance. The
optimal frequency surveillance of AAA has not been defined
by randomized clinical study. Some authors have suggested
that there is no need to follow aneurysms less than 3 cm in
diameter given their low risk of rupture.169,175 However,
McCarthy et al176 determined in a 12 year analysis of 1121
small aneurysms in 65 year-old men that 13.8% of aortas
with an initial aortic diameter of 2.6 to 2.9 cm exceeded 5.5
cm at 10 years. Among patients with an aortic diameter
between 3.0 and 3.4 cm, 2.1% had reached 5.5 cm at three
years and of those with a diameter between 3.5 and 3.9 cm,
within two years 10.5% exceeded 5.5 cm or required sur-
gery and 1.4% had ruptured.
Two randomized controlled trials, the UK Small Aneu-
rysm Trial177 and the US-based Aneurysm Detection and
Management (ADAM) Trial,3 as well as a follow-up study
of patients detected in the UK Multicenter Aneurysm
Screening Study (MASS)161 demonstrated that a policy of
surveillance until aneurysm diameter exceeds 5.5 cm was
safe and associated with a very low rate of rupture (1%/
year). While AAA size was defined by the maximum exter-
nal aortic diameter in all trials, the surveillance frequency
differed among these studies. The MASS trial scanned
patients with diameters between 4.5 and 5.0 cm at three-
month intervals, whereas the UK Small Aneurysm Trial
used six-month intervals for these patients. Patients in the
ADAM study with AAA diameter of 5.0 to 5.5 cm were
rescreened every six months, compared with every three
months in the UK. In an analysis of expansion rates among
1743 patients over a mean interval of 1.9 years, Brady et
al178 noted that AAA growth rate increased with aneurysm
size and among current smokers, was lower in those with
low ankle-brachial index and diabetes, and unaffected by
lipids and blood pressure. The authors estimated that for a
patient with a 4.5 cm AAA, the risk of enlargement to 5.5
cm was less 1% during a 12-month interval.
In summary, we recommend follow-up surveillance
imaging at 12-month intervals for patients with an AAA of
3.5 to 4.4 cm in diamater. Surveillance imaging at six-
month intervals is recommended for those patients with an
AAA diameter between 4.5 and 5.4 cm. For otherwise
healthy patients, follow-up imaging is recommended at
three years for those between 3.0 and 3.4 cm in diameter
and at five years for aneurysms between 2.6 and 2.9 cm. It
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maximum external aortic diameter.
Surveillance imaging at 12-month intervals is recommended for
patients with an AAA of 3.5 to 4.4 cm in maximum diameter.
Level of recommendation: Strong
Quality of evidence: Low
Surveillance imaging at six-month intervals is recommended for
those patients with an AAA between 4.5 and 5.4 cm in maximum
diameter.
Level of recommendation: Strong
Quality of evidence: Low
Follow-up imaging at three years is recommended for those patients
with an AAA between 3.0 and 3.4 cm in maximum diameter.
Level of recommendation: Strong
Quality of evidence: Low
Follow-up imaging at five-year intervals is recommended for patients
whose maximum aortic diameter is between 2.6 and 2.9 cm.
Level of recommendation: Weak
Quality of evidence: Low
Recommendations for imaging patients with a symp-
tomatic aneurysm. In patients with abdominal or back pain,
we recommend ultrasound imaging to determine if an AAA is
present and to identify other causes of abdominal pain or back
pain. If an aneurysm is detected, the patient should have a CT
scan to exclude rupture and be referred to a vascular surgeon.
In order to avoid delay, a CT scan is the preferred initial test in
patients with recent or severe symptoms or a pulsatile epigas-
tric mass or significant risk factors for AAA. If AAA rupture is
suspected and the patient is hemodynamically stable, an emer-
gency CT scan with contrast may be considered for preoper-
ative planning during the mobilization of the surgical team.
A CT scan is recommended to evaluate patients that present with
recent onset of abdominal or back pain, particularly in the presence
of a pulsatile epigastric mass or significant risk factors for AAA.
Level of recommendation: Strong
Quality of evidence: Moderate
TREATMENT OF THE PATIENT WITH AN AAA
The decision to treat
Patients that present with an AAA and abdominal or
back pain, even of an atypical nature, are at increased risk of
rupture and intervention is recommended. Should aneu-
rysm rupture occur, more than half of patients die prior to
hospitalization. Of those who reach the operating suite, the
outcome is dependent on the presenting clinical condition,
but typically carries a mortality of approximately 50%. For
those who present with an asymptomatic AAA, manage-
ment is dependant on the size of the aneurysm.
There is general agreement that small fusiformaneurysms,
less than 4.0 cmmaximumdiameter, are at low risk of ruptureand should be monitored and a fusiform aneurysm greater
than 5.4 cm in maximum diameter should be repaired in a
healthy patient. Elective repair is also reasonable for patients
that present with a sacular aneurysm. Debate remains for
patients presenting with AAAs between 4.0 cm and 5.4 cm
regarding the most appropriate role for either immediate
treatment or surveillance and selective repair for those aneu-
rysms that subsequently enlarge beyond 5.4 cm. In both the
United Kingdom Small Aneurysm Trial (UKSAT)179 and
AneurysmDetection andManagement (ADAM)Trial,180 the
30-day operative mortality in the immediate surgery group
(5.5% UKSAT, 2.1% ADAM) led to an early disadvantage in
survival. Investigators found no statistically significant differ-
ence in long-term survival between the immediate surgery and
surveillance groups.
Potential benefits of early surgery were noted in both the
UKSAT and ADAM study for selected subgroups.
In the UKSAT, the estimated adjusted hazard ratios were in
the direction of greater benefit of early surgery for younger
patients and those with larger aneurysms but statistical signif-
icance was not demonstrated.179 Likewise, long-term results
from the ADAM study suggested a similar effect.180 Neither
study was designed or powered to examine the question of
whether immediate surgery might be harmful for patients with
aneurysmsbetween4.0cmand4.4cm,butbeneficial forpatients
with aneurysms between 5.0 cm and 5.4 cm. Moreover, differ-
ential effects for older or younger cohorts, female patients, or
those of exceptional physiologic fitness could not be addressed.
Uncertainty regarding the potential benefit of early repair in
selected patients with small AAA is further magnified by the
demonstration that EVAR is associated with reduced periopera-
tive mortality. The Comparison of surveillance vs endografting
for small aneurysm repair (CAESAR)181 and Positive impact of
endovascular options for treating aneurysm early (PIVOTAL)
trials compare immediate EVAR with surveillance and selective
EVAR, but neither trial was designed to determine whether
immediate EVAR might be beneficial or harmful for specific
AAA size ranges or age subgroups.
Patients need to appreciate the therapeutic uncertainty
for AAA in the range of 4.0 cm to 5.4 cm. Ultimately, all
recommendations are individualized. At present, surveil-
lance with selective repair is most appropriate for older male
patients with significant co-moribidities. Young, healthy
patients, and especially women, with AAA between 5.0 cm
and 5.4 cm may benefit from early repair.
Repair is recommended for patients that present with an AAA and
abdominal or back pain.
Level of recommendation: Strong
Quality of evidence: High
Elective repair is recommended for patients that present with a
fusiform AAA 5.5 cm in maximum diameter, in the absence of
significant co-morbidities.
Level of recommendation: Strong
Quality of evidence: High
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aneurysm.
Level of recommendation: Weak
Quality of evidence: Low
Surveillance is recommended for most patients with a fusiform
AAA in the range of 4.0 cm to 5.4 cm in maximum diameter.
Level of recommendation: Strong
Quality of evidence: Moderate
Young, healthy patients, and especially women, with AAA between 5.0
cm and 5.4 cm in maximum diameter may benefit from repair.
Level of recommendation: Weak
Quality of evidence: Low
The benefit of repairing a small aneurysm is uncertain in patients
who will require chemotherapy, radiation therapy, or solid organ
transplantation.
Level of recommendation: Weak
Quality of evidence: Low
Medical management during the period of AAA
surveillance
A number of approaches have been proposed to prevent
progression of aneurysmal disease during the period of aneu-
rysm surveillance including hemodynamic control, as well as
inhibition of inflammation and protease activity.182 Several
studies have demonstrated that tobacco use is associated with
an increased rate of aneurysm expansion and smoking cessa-
tion is likely the most important recommendation that can be
made to a patient with AAA.74,156,178 Evidence from two
large randomized trials indicates that propranolol does not
inhibit aneurysm expansion.53,56 However, these results were
compromised by low compliance, with 20% to 40%of patients
discontinuing propanolol during the study period. Small ob-
servational studies suggest that 3-hydroxy-3-methylglutaryl
(HMG) coenzymeA reductase inhibitors (statins)may inhibit
aneurysm expansion.183,184 Animal studies have demonstrated
that angiotensin-converting enzyme (ACE) inhibitors or Lo-
sartan, an angiotensin receptor blocker decrease the rate of
AAA expansion. Hackam et al185 recently reported in an
analysis of 15,326 patients in linked administrative data-
Table VI. Transperitoneal or retroperitoneal approach for
Transperitoneal
Advantages ● Most rapid, greatest flexibility
● Provides widest access
● Enables evaluation of intra-abdominal patho
Disadvantages ● Longer ileus
● Potential for greater fluid losses
● Difficulty with exposure and control for jux
or pararenal AAAAAA, Abdominal aortic aneurysm.bases that use of ACE inhibitors within the prior three to 12
months was less frequent among those patients with AAA
rupture. Beta-blockers, lipid-lowering agents, and angio-
tensin receptor blockers showed no relationship to rupture.
Further, Lederle and Taylor186 observed an increased risk of
aneurysm rupture among those patients who discontinued
ACE inhibitors within the past three to 12 months. Lindholt
et al187 have suggested that serological evidence of a C.
pneumoniae infection is associated with an increased rate of
AAA expansion and small randomized trial of approximately
100 patients demonstrated that a one month course of rox-
ithromycin decreased the rate of aneurysm expansion.188 A
number of studies have suggested that doxycycline can inhibit
matrixmetalloproteases in plasma and aneurysm tissue.189,190
Morosin et al191 randomized 32 patients with AAA to doxy-
cycline (150 mg/d) or placebo for three months. Patients
were followed for 18 months. C. pneumoniae titers were not
affected by doxycycline treatment. A trend toward a lower
AAA growth rate was observed in the doxycycline-treated
group. Additional studies are needed to clarify the potential
role of doxycycline, roxithromycin, and statin therapy in the
progression of aneurysmal disease.
In summary, during the surveillance period, patients
should be counseled to cease smoking if tobacco products are
being utilized. Patients should be encouraged to seek appro-
priate management for hypertension, hyperlipidemia, diabe-
tes, and other atherosclerotic risk factors. A statin and ACE
inhibitor should be initiated given their broad potential ben-
efits and acceptable safety profile. Insufficient data exists to
recommend use of doxycycline or roxithromycin. Patients
should be counseled that moderate physical activity does not
precipitate rupture and may limit AAA growth rate.192
Screening of family members should be recommended.
Smoking cessation is recommended to reduce the risk of AAA
growth and rupture.
Level of recommendation: Strong
Quality of evidence: High
Statins may be considered to reduce the risk of AAA growth.
Level of recommendation: Weak
Quality of evidence: Low
n abdominal aortic aneurysm repair
Retroperitoneal
● Avoids hostile abdomen
● Facilitates exposure and control for juxta-pararenal AAA
● Potential for less ileus, other physiologic stress
● Obesity
● Inflammatory AAA/horseshoe kidney
● Poor access to right renal and iliac arteries
● Cannot evaluate intra-abdominal pathology
● Longer to open and close
● More flank bulges, chronic wound painope
logy
ta –
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receptor blockers are of uncertain benefit in reducing the risk of
AAA expansion and rupture.
Level of recommendation: Weak
Quality of evidence: Low
The use of beta blockers to reduce the risk of AAA expansion and
rupture is not recommended.
Level of recommendation: Strong
Quality of evidence: Moderate
Screening for AAA is recommended for first degree relatives of
patients presenting with an AAA.
Level of recommendation: Strong
Quality of evidence: High
Open surgery
Once the need for AAA repair has been determined, a
choice will need to be made between conventional OSR
and EVAR. The basic technique of endoaneurysmorrhaphy
first popularized by Creech193 emphasizes minimal dissec-
tion and intrasaccular ligation of lumbar artery branches,
with suture attachment of the prosthetic graft to the prox-
imal and distal aspects of the aneurysm. This, together with
steady advances in graft and suture materials, surgical expe-
rience, and perioperative anesthesia and critical care, have
made conventional OSR a very successful and durable
correction for aortoiliac aneurysmal disease.
Operative approach. For standard open operative re-
pair, an anterior transperitoneal (TP) or left-flank retroperito-
neal (RP) approach may be employed. Each method has its
own potential advantages and limitations (Table VI). In addi-
tion, the individual training and personal experience of the
surgeon may also influence decision-making in this regard.
A TP approach via a generousmidline abdominal incision
is most commonly employed for infrarenal AAA repair, and
most familiar to surgeons. This exposure can be performed
rapidly, provides wide intra-abdominal access and maximal
flexibility, and enables evaluation of other possible intra-ab-
dominal pathology. In contrast to the typical midline vertical
incision, a few surgeons recommend a transverse incision just
above or below the umbilicus, as they believe such incisions
may result in less postoperative pulmonary complications or a
lower incidence of incisional hernias in long-term follow-up.
However, such claims have never been clearly established and
transverse incisions are infrequently utilized.
Advocates of a RP approach claim various physiologic
benefits, including reductions in fluid losses, cardiac stress,
postoperative pulmonary complications, and severity of
ileus. All of these potential benefits are felt to lead to a
reduction in ICU and hospital length-of-stay, diminished
costs, and quicker recovery. However, several randomized
prospective studies examining these possible advantages of
a RP approach have reached differing conclusions. Cambria
and colleagues194 did not detect any of the physiologic
benefits observed by Sicard and co-workers195 other than a
shorter duration of postoperative ileus and slightly earlierresumption of oral intake. A more recent randomized com-
parison of TP and RP approaches for infrarenal aortic
surgery by Sieunarne et al196 also failed to document any
significant physiologic or other perioperative outcome dif-
ferences, but did note a higher evidence of long-term
wound problems, including incisional pain, bulges, and
hernias in the RP group.196 Such conflicting results suggest
that the choice of surgical approach is best individualized in
each patient, based upon individual anatomic and clinical
circumstances. A RP approach may be preferable for pa-
tients with a “hostile abdomen” secondary tomultiple prior
intra-abdominal operations, a history of irradiation, pres-
ence of abdominal hernias, stomas, or marked obesity.
Similarly, most vascular surgeons agree that a RP incision is
preferred for repair of inflammatory aneurysms or AAA
associated with a horseshoe kidney.197,198
In current practice, perhaps the clearest indication for a
RP approach is extension of aneurysmal disease to the
juxtarenal or visceral aortic segment. Exposure and control
of the aorta in this region, as well as the left renal and
visceral branches, are facilitated by a left lateral RP approach
and opening of the left diaphragmatic crura. Use of an
extended posterolateral RP approach with the left kidney
mobilized anteriorly has the additional advantage of trans-
posing the left renal vein anteriorly, thereby avoiding the
possible need to divide the left renal vein to gain adequate
exposure of the juxtarenal or suprarenal aorta which may
be required on occasion with an anterior TP approach.
While some authorities feel the left renal vein may be
divided without consequence as long as collateral branches
are preserved, several other reports document some adverse
impact on renal function.77,199 Use of an RP approach
avoids this dilemma. The ease and flexibility of exposure
and clamping of the suprarenal or supravisceral aorta via
this approach has even led some investigators to advocate
use of a high extended posterolateral approach for emer-
gency repair of ruptured aneurysms.200 Good results have
been achieved, without the potential consequences of en-
tering the area of retroperitoneal hematoma and loss of the
tamponade effect which has long been a concern expressed
by many surgeons for such an approach.
Because many infrarenal AAA with favorable neck anat-
omy are currently repaired with endovascular stent grafts, in
contemporary practice, all vascular surgeons recognize that
the technical complexity and challenges of OSR have in-
creased since only aneurysms with adverse neck anatomy not
felt suitable for EVAR undergo standard OSR.201-203 It is
clear, therefore, that a vascular surgeon should be familiar and
experiencedwith both aTP andRPapproach, utilizing each as
determined by patient anatomy and clinical need.
A retroperitoneal approach should be considered for patients in
which aneurysmal disease extends to the juxtarenal and/or visceral
aortic segment, or in the presence of an inflammatory aneurysm,
horseshoe kidney, or hostile abdomen.
Level of recommendation: Strong
Quality of evidence: Moderate
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with a transverse abdominal incision may be considered for patients
with significant pulmonary disease requiring OSR.
Level of recommendation: Weak
Quality of evidence: Low
Division of the left renal vein may be considered to gain suprarenal
aortic exposure.
Level of recommendation: Strong
Quality of evidence: High
Aortic clamping. For standard infrarenal AAA, prox-
imal aortic clamp placement is below the renal arteries, but
should be as close to the renal vessels as feasible in order to
perform the proximal graft anastomosis as high as possible.
This is emphasized in order to minimize the incidence of
late development of recurrent aneurysmal degeneration
above the graft, which may occur if the anastomosis is
performed at a low level on the aorta.
If an anterior TP approach has been employed, it may
be necessary to mobilize the crossing left renal vein and
retract it superiorly to allow high proximal clamp applica-
tion. This may require division of its gonadal and posterior
lumbar branches to avoid tearing and injury to the vein.
Complete division of the vein is best avoided in view of its
possible adverse impact on postoperative renal dysfunction.
If the renal vein is to be divided, the decision should be
made prior to division of the gonadal, adrenal, and lumbar
branches, which provide collateral flow from the left kid-
ney. Alternatively, end-to-end anastomosis of the divided
renal vein may be considered.
The proximal extent of aneurysmal disease and quality of
the aorta at the anticipated clamp site are best determined by
careful examination of a high-quality fine-cut abdominal CT
scan, both with and without contrast to allow accurate iden-
tification of aortic wall calcification and the extent of athero-
matous debris and the length and diameter of the aneurysm
neck. While there are essentially no anatomic constraints to
OSR as exist for EVAR, careful preoperative evaluation of
aortic and aneurysmal anatomy are nonetheless important
aspects of preoperative planning prior to operation.
If extensive calcification or intraluminal atheromatous
disease is noted, or the aneurysm extends very close to the
renal arteries, a decision to clamp at a higher level becomes
advisable to minimize the risk of atheromatous emboliza-
tion into the renal arteries or clamp injury to the aortic wall.
Whether the clamp is placed suprarenal but below the
visceral arteries, between the superior mesenteric (SMA)
artery and celiac axis, or at a supraceliac level is dependent
upon anatomy and aortic quality at these varying levels.
Often there is little room between the renal arteries and
SMA, or between the two visceral branches, to allow safe
dissection and clamp application. If pararenal atheromatous
disease or significant calcification is observed on the CT
scan, it will likely be preferable to go to a supraceliac level to
minimize the risk of renal embolization or flow obstruc-
tion, despite the possibility of increased hemodynamic andcardiac stress.204,205 Although suprarenal clamping is asso-
ciated with an increased risk of postoperative decrease in
renal function and overall adverse events, 30-day mortality
is comparable to those patients repaired with infrarenal
crossclamping.206,207
It is usually recommended that the proximal clamp be
applied first, in order to minimize the occurrence of athero-
matous embolization. This has never been truly studied or
established, however, it would seem reasonable to clamp the
least diseased arterial segment first, whether proximal or distal,
in order to accomplish this objective.Distal clamping is almost
always at the iliac level, since aneurysmal disease usually ex-
tends close to the aortic bifurcation even in patients suitable
for a straight tube graft reconstruction. As with determination
of the best site for proximal clamping, the surgeon should
evaluate the preoperative CT scan, as well as palpate the iliac
arteries at surgery, to determine the best site and method of
distal clamping. If severely calcified, intraluminal control of
the iliac arteries with balloon catheters will be a safer andmore
effectivemethodof control.Useof soft-jawed clampsmay also
be considered. Because iliac plaque and disease is most often
posterior, clamping in a transverse planemay also be safer than
the typical anteroposterior (AP) application.
Irrespective of clamp location and method, systemic hep-
arinization (75-100U/kg) is utilized by almost all vascular
surgeons for elective AAA repair. In the circumstances of a
ruptured aneurysm or other unusual situations, heparin may
be omitted, with vigorous flushing of the graft prior to restor-
ing blood flow, or limited amounts of heparinized saline may
be instilled directly into distal vessels after placement of the
proximal clamp. For patients with a history of heparin-induced
thrombocytopenia, a thrombin inhibitor (eg, Bivalirudin, Ar-
gatroban) is recommended at the time of aortic clamping.
A high-quality preoperative CT scan is recommended to determine
the optimal site of proximal aortic clamping based upon the extent
of aneurysmal disease and quality of the aorta.
Level of recommendation: Strong
Quality of evidence: High
A transbrachial or transfemoral balloon for aortic control may be
considered prior to anesthetic induction for patients with a
ruptured aortic aneurysm.
Level of recommendation: Weak
Quality of evidence: Low
A thrombin inhibitor (eg, Bivalirudin, Argatroban) is
recommended at the time of aortic clamping for patients with a
history of heparin-induced thrombocytopenia.
Level of recommendation: Strong
Quality of evidence: Moderate
Type and configuration of the graft. Excellent pa-
tency and long-term results have been achieved with a wide
variety of prosthetic grafts utilized for open AAA repair.
Numerous modifications of graft material, such as polyester
or polytetrafluoroethylene (PTFE), methods of fabrication,
including knitted or woven, external or double velour, high
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performance and other characteristics such as ease-of-
handling, durability, healing, resistance to infection, or
reduced dilatation over time. One may conclude, however,
that patency and other late outcomes appear to be equiva-
lent for grafts placed in the aortic position. Hence surgeon
preference and cost are usually the dominant determinants
in aortic graft choice.208-210 Currently, “zero porosity”
polyester grafts, rendered impermeable by various biologic
coatings, such as collagen, gelatin, or albumin, are the most
popular and widely employed. Although more expensive,
their expediency, intraoperative time savings, and reduced
blood loss attributable to the lack of preclotting require-
ments more than offset such costs.
Aorto-aortic “straight tube” grafts are generally re-
garded as preferable to bifurcated prostheses due to a
shortened operative time, reduced blood loss, and less need
for dissection with attendant risk of injury to adjacent
structures such as the ureter, iliac veins, or autonomic nerve
networks. In most series of elective open aortic graft repair,
tube grafts are utilized in 40% to 50% of cases, although the
proportion of straight tube or bifurcated configuration
varies in the literature range between 0% and 85%.211 In the
Canadian Aneurysm Trial, for example, 38.5% of AAA
grafts were tube grafts, aortobiiliac in 30.7%, iliac-femoral
distal anastomoses in 6.5%, and aortobifemoral in
24.3%.212 Certainly bifurcated grafts are advisable if clini-
cally significant concomitant iliac aneurysms (2.0 cm to
2.4 cm) are present. Prior reports have suggested that iliac
aneurysms may be present in 20% to 30% of patients with
infrarenal AAA.212,213 If coexistent symptomatic aortoiliac
occlusive disease exists with limiting claudication, both
aneurysmal and obliterative disease can be corrected with
an aortobifemoral graft. However, a somewhat higher in-
cidence of wound infection, graft limb thrombosis, and
anastomotic aneurysm has been reported if the graft is
extended to the groin.212
If significant iliac aneurysmal or occlusive disease is not
present at the time of repair, many series have documented
a low incidence of late disease progression necessitating
reintervention.211,214 Thus, the surgeon can be confident
in placement of a tube graft at the time of initial repair. In
addition, current increased endovascular options for stent
grafting and/or balloon angioplasty/stenting offers assur-
ance that any late problems developing in the iliac arteries
that may require reintervention can likely be managed by
catheter-based therapies.
Benefit from the prophylactic use of rifampicin impreg-
nation of prosthetic graft material in preventing early or late
graft infection has not been identified in three multicenter
studies including 3,379 patients. In all cases, gelatin-coated
Dacron grafts were soaked in 1mg/mL of rifampicin for 15
minutes before insertion. The Joint Vascular Research
Group trial215,216 included patients undergoing extra-
anatomical grafts (axillofemoral, femorofemoral, and il-
iofemoral crossover grafts) whereas the Italian Investigators
Group217 included patients undergoing mono-, bifemoral,
or iliofemoral grafts.Straight tube grafts are recommended for OSR of AAA in the
absence of significant disease of the iliac arteries.
Level of recommendation: Strong
Quality of evidence: High
The proximal aortic anastomosis should be performed as close to the
renal arteries as possible.
Level of recommendation: Strong
Quality of evidence: High
It is recommended that all portions of an aortic graft should be
excluded from direct contact with the intestinal contents of the
peritoneal cavity.
Level of recommendation: Strong
Quality of evidence: High
Maintenance of pelvic circulation. Blood supply to
the left colon and pelvic organs is comprised of a complex
network, with contributions from the SMA to the inferior
mesenteric artery (IMA) via themeanderingmesenteric artery
and marginal artery of Drummond, the internal iliac or hypo-
gastric arteries, and collateral vessels from circumflex branches
of the common and deep femoral arteries. Failure to properly
maintain pelvic bloodflowduring aneurysm repairmay lead to
a variety of problems, including postoperative sexual dysfunc-
tion, troublesome hip and buttock claudication, or, more
significantly, colon ischemia or infarction and possible spinal
cord ischemia or infarction with paraparesis or paraplegia.
Thus, the status of pelvic blood supply must be assessed
preoperatively, and steps taken during surgery to maintain
adequate colonic and pelvic circulation.
Although multifactorial in origin, ligation of a patent
IMA is the most commonly noted risk factor for develop-
ment of colon ischemia in many series.218 While the IMA
may already be occluded at the time of surgery in 40% to
50% of patients secondary to concomitant occlusive disease
or intrasaccular mural thrombus, the IMA is patent in over
one-half of patients.219 Whether or not to reimplant a
patent IMA into the aortic graft remains controversial.
Some authors have recommended frequent or even routine
reimplantation of a patent IMA,219,220 but its value has not
been clearly established.221,222 A prospective randomized
trial examining this question found no statistically signifi-
cant reduction of perioperative colon ischemia with reat-
tachment and preservation, although the data did suggest
that older patients or those with increased intraoperative
blood loss might benefit from reimplantation.223
It seems reasonable to conclude that IMA reimplanta-
tion should be considered in the presence of associated
celiac or SMA occlusive disease, an enlarged meandering
mesenteric artery, a history of prior colon resection, inabil-
ity to preserve hypogastric perfusion, poor IMA backbleed-
ing, poor Doppler flow in colonic vessels, or should the
colon appear ischemic. Prediction and prevention of colon
ischemia remain of paramount importance, which carries
up to a 50% mortality if transmural colonic infarction
occurs. The surgeon should first ascertain the status of the
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the time of operation, the vessel can be readily interro-
gated with a sterile hand-held Doppler when the aneu-
rysm is first exposed. If a patent IMA is present, it should
not be ligated or divided, but rather controlled with a
bulldog clamp or silastic loop. If the vessel is large,
particularly if co-existent celiac or SMA occlusive disease
is present or an enlarged meandering mesenteric collat-
eral network is noted, preservation and reimplantation is
warranted. A history of prior colon resection may be
presumed to have compromised SMA to IMA territory
collateral blood flow, and may also suggest the advisabil-
ity of replanting a patent IMA. Inability to restore pre-
existent hypogastric blood flow may be another impetus
to reimplant a patent IMA. Finally, poor back bleeding
from a patent vessel once graft reconstruction has been
completed and distal blood flow restored suggests inad-
equate collateral flow and the likely need to reimplant
the IMA. This may be associated with an ischemic ap-
pearance of the colon and abnormal or absent Doppler
signals in the colonic arcade or anti-mesenteric bowel
wall. If clamp time has been prolonged, blood loss
substantial, or periods of significant intraoperative hypo-
tension have been present, as in the case of a repair of a
ruptured aneurysm, the threshold to proceed with reim-
plantation should be lower. In the Canadian Aneurysm
Study, the IMA was reimplanted in 4.8% of cases, but was
associated with an increased incidence of postoperative
bleeding.77 If IMA reimplantation is elected, most sur-
geons accomplish this by preservation of a small island of
aneurysm wall tissue around the orifice of the vessel and
suturing of this “button” of tissue into a small opening in
the graft as a Carrel patch.
It has long been accepted as a basic principle of aortic
reconstruction that blood flow to at least one internal iliac
artery should be maintained. Failure to achieve this has
usually been felt to result in problems with erectile dysfunc-
tion, symptomatic hip and buttock claudication, or occa-
sionally colon ischemia, buttock necrosis, or spinal cord
(cauda equina) ischemia. For example, in the Canadian
Aneurysm Study, the incidence of clinically apparent colon
ischemia was 0.3% when hypogastric flow was preserved to
at least one side, while it was 2.6% when flow was lost
bilaterally. The one case of paraplegia in this report oc-
curred in a patient in whom pelvic blood flow was not
maintained.212
Recently, the necessity to preserve perfusion of a least
one hypogastric artery has been questioned as endovascular
stent graft aneurysm repair has become more widely uti-
lized. Mehta and associates reported no mortality or signif-
icant morbidity in a series of 48 patients requiring interrup-
tion of flow to both hypogastric arteries as part of
endovascular (n  32) or open surgical (n  16) repair of
aortoiliac aneurysms;224 however, they noted buttock clau-
dication symptoms in 42% and new onset of erectile dys-
function in 14%.
While firm conclusions on this topic cannot be
reached with certainty, it seems prudent to make everyeffort to preserve hypogastric perfusion on at least one
side. During OSR, this can usually be achieved, even in
patients with fairly extensive iliac aneurysmal disease, by
distal anastomosis at the iliac bifurcation, or by end-to-
side anastomosis to the external iliac artery and preser-
vation of retrograde perfusion to the internal iliac. On
rare occasions, a separate short “side arm” graft can be
constructed directly to the internal iliac to maintain flow.
Similarly, when preservation of at least one hypogastric
artery during EVAR is difficult, some investigators rec-
ommend concomitant surgical bypass from the external
to internal iliac prior to or at the time of endovascular
repair to maintain pelvic circulation.225,226
Reimplantation of a patent inferior mesenteric artery (IMA)
should be considered under circumstances that suggest an increased
risk of colonic ischemia.
Level of recommendation: Strong
Quality of evidence: High
It is recommended that blood flow be preserved to at least one
hypogastric artery in the course of OSR or EVAR.
Level of recommendation: Strong
Quality of evidence: High
Management of associated intra-abdominal non-
vascular disease. With increasing use of preoperative CT
scans and other imaging modalities for preoperative evalu-
ation of aortic aneurysms, associated intra-abdominal pa-
thology may be detected. Conversely, it is quite common
for an unsuspected aneurysm to be initially detected during
radiologic studies to evaluate other intra-abdominal condi-
tions. Unsuspected intra-abdominal pathologies may be
found at the time of abdominal exploration duringOSR. In
all of these scenarios, there is considerable uncertainty
about the timing of AAA repair by OSR or EVAR and
management of other intra-abdominal pathology. In many
instances of combined disease, EVAR is particularly attrac-
tive, allowing quicker recovery from aneurysm repair and
facilitating earlier correction of the associated condition.
General guidelines for decisionmaking in these circum-
stances emphasize treatment of the most life-threatening or
symptomatic problem first; simultaneous combined repair
of both lesions is generally avoided, particularly in circum-
stances where bacterial contamination (eg, gastrointestinal,
genitourinary) of the prosthetic aortic graft might occur
with potentially devastating consequences.
In regard to colonic malignancies, resection of the
tumor or diverting colostomy should be performed only for
instances of impending obstruction, significant bleeding, or
perforation. Otherwise, isolated aneurysm repair takes pre-
cedence, with subsequent colonic operation in four to six
weeks. Initial colonic resection prior to AAA repair is
generally unwise in elective circumstances, as any septic
complications after bowel resection may delay aneurysm
repair formanymonths.227 In contrast, simultaneous repair
of “clean” lesions, such as renal or ovarian tumors, may be
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ted.228 Although gallstones may be found in 5% to 15% of
patients undergoing AAA repair, post-operative cholecysti-
tis followingOSR or EVAR is rare.229 Thus, themotivation
for concomitant cholecystectomy is limited, especially
given the potential for direct contamination of the graft
should bile leakage or spillage occur.
Concomitant surgical repair of an AAA and co-existent intra-
abdominal pathology may be considered in highly selective
circumstances.
Level of recommendation: Strong
Quality of evidence: High
Unusual aneurysms
Juxtarenal aneurysms. Aneurysms that extend close
to the origins of the renal arteries and thereby require
suprarenal aortic clamping to allow repair are termed jux-
tarenal aneurysms. Because endovascular stent graft repair
is performed in 40% to 70% of patients with standard
infrarenal AAA in current practice, such juxtarenal aneu-
rysms represent an increasing percentage of open surgical
repairs.202 Due to the technical challenges of adequate
surgical exposure and aortic control, as well as a period of
obligatory renal and/or visceral ischemia and increased
cardiac stress as a consequence of suprarenal or supraceliac
clamping, repair of juxtarenal AAA is more complex and
associated with increased perioperative morbidity and mor-
tality risk.202,230,231 Thus, because of the increased risk of
repair, many vascular surgeons feel that operation may not
be indicated until the aneurysm reaches a greater maximum
diameter than the threshold size for a standard infrarenal
AAA.
When extension of aneurysmal disease to the juxtarenal
level is recognized from the preoperative CT scan, modifi-
cations of operative strategies regarding approach and
clamp placement must be considered.Most surgeons prefer
a left flank extended retroperitoneal approach, but others
recommend an anterior approach with transcrural suprace-
liac clamping or medial visceral rotation.202,230,231 The
exact site of proximal aortic clamp placement is determined
by anatomy with principal emphasis on extent of aneurys-
mal and associated aortic atherosclerotic disease. The prox-
imal graft anastomosis is then performed just below the
renal artery origins. By definition, renal artery bypass graft-
ing or reimplantation is not required in juxtarenal AAA
repair unless mandated by co-existent renal artery disease.
Inflammatory aneurysms. Inflammatory AAAs are
characterized by amarkedly thickened aortic wall and dense
perianeurysmal fibrosis. As a consequence of this fibrotic
process, neighboring structures such as the duodenum, left
renal vein, and ureters are often densely adherent to the
aneurysm sac, making open surgical repair of such aneu-
rysms more challenging and possibly associated with a high
incidence of perioperative injuries or complications.232
Recognition of an inflammatory aneurysm is usually possi-
ble from the preoperative scan, which reveals the markedlythickened aneurysmal wall with a “halo” of soft tissue
around the aneurysm, which enhances with administration
of intravenous contrast.
If an inflammatory aneurysm is suspected, EVAR is a
preferred approach. Otherwise, several principles should be
considered if an inflammatory AAA is treated byOSR. Should
the perianeurysmal process obstruct the ureters, preoperative
insertion of ureteral stents may be helpful in alleviating hydro-
nephrosis, as well as in facilitating identification of the ureters,
thereby minimizing the danger of ureteral injury during op-
erative repair. In most cases, repair of the aneurysm leads to
regression of the perianeurysmal fibrosis and relief of ureteral
obstruction. Most authors urge caution in attempting ureter-
olysis at the time of surgery in order to relieve obstruction due
to the significant risk of ureteral injury and leakage. Many
vascular surgeons favor a retroperitoneal approach for repair of
inflammatory aneurysms as the chance of injuring adjacent
organs or structures is reduced and the flexibility of proximal
clamp placement enhanced.198,233
In patients with inflammatory aneurysms who have
otherwise suitable anatomy, EVAR may provide a particu-
larly useful alternative to OSR. The potential technical
difficulties of OSR are avoided, and multiple reports of
successful endovascular repair leading to subsequent im-
provement in the extent and severity of the perianeurysmal
and retroperitoneal fibrotic process, similar to that seen
following conventional OSR, have been published.234,235
Horseshoe kidney. Advanced knowledge of a horse-
shoe, ectopic, or pelvic kidney associated with an AAA is
particularly important in view of the frequently complex
renal artery anatomy, possibility of anomalous ureteral
drainage, and other technical challenges for OSR. The
diagnosis is usually evident on preoperative CT scans. Be-
cause multiple renal arteries are encountered in 75% of
cases, often arising from the aneurysmal aortic segment,
detailed preoperative arteriographymay be required to fully
elucidate the aberrant origin and location of renal blood
supply and facilitate operative planning.197,236
If a horseshoe kidney is encountered unexpectedly during
open AAA repair via an anterior transperitoneal approach, the
isthmus of the horseshoe should not be divided unless it is
extremely thin and atrophic, due to concern regarding injury
to a renal collecting system and resultant urinary leakage. In
such circumstances, the surgeon should try to mobilize and
elevate the renal isthmus, and tunnel the graft beneath it.
Careful dissectionwill be necessary to identify andpreserve the
principal renal circulation.
Ideally, preoperative recognition and appropriate de-
lineation of renal artery anatomy will allow a retroperito-
neal approach, which most surgeons prefer for repair of an
AAA with horseshoe kidney. With a flank approach, the
bulk of renal tissue can be easily displaced anteriorly and
thereby avoided, and anomalous renal arteries originating
from the AAA more easily preserved by reimplantation,
short renal artery grafts, or revascularization from within
the AAA sac.197,236,237 In the 25% of cases with single main
renal arteries originating in a normal location above the
aneurysm, patients with suitable proximal and distal anat-
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avoidance of the technical challenges associated with open
operation.
Aortocaval fistula. Spontaneous aortocaval fistula is
an infrequent complication of an AAA with a 2% to 4%
incidence of ruptured aneurysms associated with a venous
fistula. The mortality rate is approximately 30%.238 Pre-
sumably the fistula forms as a result of necrosis of the aortic
wall leading to an adventitial inflammatory reaction that
eventually leads to rupture at the aortic-caval interface.
Aortocaval fistulas most often present in men with an
average age of 65 years. Patients may complain of confu-
sion, lethargy, abdominal or low back pain, or dyspnea. A
palpable abdominal mass with a loud machinery murmur is
typically present on exam. High output failure with ele-
vated central venous pressure, pulmonary edema, lower
limb edema, pulsating varicose veins, hematuria, rectal
bleeding, or priapism may also be present.
Both ultrasonography andCT scanningmay demonstrate
the presence of the fistula. Given the intense inflammatory
reaction at the site of fistula formation, proximal and distal
control is most safely achieved by direct compression above
and below the fistula within the aneurysm sac. An aortocaval
fistula carries an increased risk for massive hemorrhage or air
embolism. The fistula is usually closed primarily with nonab-
sorbable suture. Several reports have described successful
EVAR of AAA with spontaneous aortocaval fistula.239-241
Primary aortoenteric fistula. Primary aortoenteric
fistula is a rare event often characterized by a classical triad
of gastrointestinal bleeding, pain, and a pulsatingmass that,
in fact, is present in only a minority of patients.242 Most
primary aortoenteric fistulas are caused by an aneurysmal
aorta and are almost always heralded by repetitive gastro-
intestinal bleeding. The time interval between the first
herald bleed and massive exsanguination may range from
hours to months. Computed tomography that demon-
strates air within the aortic wall and contrast within the
gastrointestinal tract strongly suggests the presence of a
fistula. Indeed, gastrointestinal bleeding combined with a
negative endoscopy in the presence of a known AAA sug-
gests a primary aortoenteric fistula and mandates an urgent
CT. Controlled hypotension with maintainenance of sys-
tolic blood pressure between 60 mm Hg and 100 mm Hg
may reduce the risk of recurrent hemorrhage during the
period leading up to repair. The fistula commonly involves
the third or fourth portion of duodenum in over half of
cases, but may also involve the stomach, esophagus, or jeju-
num. Surgical approaches continue to carry an attendant
mortality of 30% to 40%. Extranatomic bypass with repair of
the intestinal defect is recommended, while in situ graft repair
using an ePTFE prosthesis is appropriate in the unstable
patient. A portion of omentum should bewrapped around the
vascular anastomosis or closure site and the overlying intes-
tine.Closure of the gastrointestinal defect alonewithout treat-
ment of the aneurysm is not recommended. Operative cul-
tures should be obtained and appropriate antibiotic treatment
initiated. EVAR may allow an unstable patient to undergo
later definitive repair on an elective basis. A drawback ofendovascular treatment is the risk of overwhelming sepsis
because of a persistent source of untreated infection.
Primary mycotic abdominal aortic aneurysm. A
mycotic aneurysm of the abdominal aorta may result from
primary aortitis, septic emboli, or an adjacent infection,
such as pancreatitis or a psoas muscle abscess. Mycotic
aortic aneurysms may be suggested by preoperative imag-
ing with associated rupture a common feature. Salmonella
and staphylococcus are common organisms.243 Recom-
mended approaches for intervention are similar to those
described for treatment of an aortoenteric fistula. Clinical
results of medical treatment alone with antibiotic therapy
remain poor.244 Recently, EVAR has also been applied in
the treatment of mycotic aortic aneurysms with mixed
results. In a review of 48 cases from 22 reports, Kan et al245
identified rupture or fever at presentation, as well as persis-
tent fever after EVAR as predictive of poor outcome and,
under these circumstances, recommended definitive surgi-
cal treatment or use of EVAR as a ‘bridge’ to surgical
therapy. Nonetheless, better outcomes were noted in the
absence of these feastures and when preoperative antibiotic
suppression was associated with negative blood cultures
before intervention. Further study of the role of EVAR in
this difficult problem is warranted.
AAA secondary to Type IV Ehlers-Danlos syn-
drome (EDS). Diagnostic arteriography, in patients with
type IV EDS has been associated with a 17% to 67%
complication rate, including tears, dissection, perforation,
and pseudoaneurysm formation, with 6% to 19% mortal-
ity.246 Blood vessels display a “wet-tissue” consistency and
may fail to hold sutures. Use of Teflon pledgets along with
fibrin glue is recommended. Succesful endovascular repair
has been reported and, if anatomically feasible, should be
considered the preferred approach for treatment.247
Preoperative insertion of ureteral stents should be considered for
patients undergoing OSR of an inflammatory aneurysm,
particularly in the presence of hydronephrosis.
Level of recommendation: Strong
Quality of evidence: High
Timing of surgery. A ruptured AAA clearly represents
a true surgical emergency. Documented rupture, particularly
with associated hypotension, demands immediate transfer to
the operating room as rapidly as possible. The timing of
surgical repair in patients with symptomatic but unruptured
aneurysms remains more controversial. A patient with a
known AAA or pulsatile mass on abdominal exam who pre-
sents with acute onset of back or abdominal pain should
undergo an immediate contrast enhanced CT scan to deter-
mine if rupture has occurred. The timing of AAA repair for
those patients with symptomatic but unruptured aneurysms
represents a clinical dilemma. Many series have demonstrated
a significantly higher operative mortality for patients with
symptomatic but unruptured AAA who undergo emergent
open repair.248-250 For example, Sullivan et al noted a five-
fold increase in mortality (26% vs 5.1%) for patients with
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contrast to elective repair.249 Similarly, Haug and co-workers
observed a mortality rate of 18% in patients with symptomatic
AAA who underwent surgical repair within 24 hours versus
4.2% for those with semi-elective repair following emergency
admission or patients having elective surgery.248 In theMayo
Clinic series, no deaths from rupture occurred among those
patients whose operation was delayed.251
The reason for such differences in outcome are multi-
factorial, but include the fact that truly emergency surgical
repair is often carried out in less favorable circumstances
without the usual surgical and anesthesia personnel or at
times outside the typical workday. Similarly, some patients
may benefit from preoperative preparation or interventions.
Although definitive recommendations are not possible, and
each clinical situation must be approached individually, it
may be prudent to delay truly emergent repair of symptom-
atic but unruptured aneurysms for four to 24 hours until
optimal conditions may be achieved. If such an approach is
elected, blood should be available and the patient cared for
in an ICU-setting prior to operation.
A related practical concern regarding timing of opera-
tion, which frequently arises but for which there is practi-
cally no data relates to the scheduling of elective repair in
asymptomatic patientswith largeAAA.While the definition of
“large” AAA is ill-defined, it is well accepted that the rupture
risk of AAA 6 cm to 7 cm in diameter ranges from 10% to 20%
per year, 7 cm to 8 cm 20% to 40%, and those8 cm 30% to
50%.1 However, these are estimates for rupture risk over
a 12 month period, and the rupture risk within a period
of weeks or one to two months remains completely
unknown. There is certainly no standard of care in regard
to the time period within which elective repair must be
carried out. While clearly there is little advantage in
excessive delay in performing elective repair of a large
AAA, it is appropriate to obtain pertinent preoperative
studies and tests in a timely fashion, particularly in older,
high-risk individuals. Similarly, if preoperative interven-
tion may potentially make such a patient a more favor-
able candidate for operation, then some delay appears
warranted. On occasion, however, rupture may occur
during this interval. Although completely unpredictable,
it is recommended that this decision-making be made
with the patient and family, and that they understand
and accept such a small risk.
Immediate repair is recommended for patients that present with
documented aneurysm rupture.
Level of recommendation: Strong
Quality of evidence: High
Should repair of a symptomatic AAA be delayed to optimize
associated medical conditions, it is recommended that a patient be
monitored in an ICU-setting and blood products be available.
Level of recommendation: Strong
Quality of evidence: HighA final issue in regard to timing is whether or not a
recent prior procedure, such as a laparotomy, coronary
revascularization, or other operations can increase the like-
lihood of AAA rupture and represent an indication for
earlier AAA repair. This has been a long-standing contro-
versy, with anecdotal experience suggesting that this is
indeed the case.252,253 It has been suggested that a balance
between the dynamic equilibrium of collagen synthesis and
lysis might be altered by such operations, with injury, local
inflammation, and possible nutritional depletion resulting
in enhanced lysis of collagen and increased AAA rupture
risk. However, Cohen et al254 examined this question in
rats, and found no evidence of increased aortic collagenase
activity, and a prospective clinical study on this topic by
Durham and colleagues found no evidence of this phenom-
enon.255 It seems reasonable to conclude that the risk of
AAA rupture is not increased by such unrelated surgeries,
and that a period of four to six weeks should be allowed to
enable a satisfactory recovery to occur prior to elective AAA
repair. Certainly this should be modified if the aneurysm is
symptomatic, large, or other worrisome features are iden-
tified on CT scan. Similarly, if endovascular repair is feasi-
ble, a shorter interval between operative procedures may be
justified.
Perioperative outcomes of open AAA repair. Perio-
perative 30-day mortality of conventional OSR varies con-
siderably in the literature. Much of this variability appears
related to the type of study reported, that is, hospital-based
versus population-based series, and whether or not the
reports were prospective or retrospective studies.256 Over
the past two decades, mortality risk of elective infrarenal
AAA repair in referral-based single institution reports from
selected centers of excellence has ranged from 1% to
4%.1,76,257-259 In multiple population-based series, how-
ever, employing state-wide or nation-wide data bases, re-
ported perioperative mortality rates have generally been
Table VII. Estimated perioperative complications after
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Elsevier Saunders; 2005. p. 1431.in the 4% to 8% range even in contemporary experi-
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perioperative mortality risk of endovascular repair. Simi-
larly, perioperative morbidity associated with OSR, partic-
ularly, cardiac, pulmonary, or renal complications, as well as
the incidence of colonic ischemia exceeds that of EVAR.
Complications after open AAA repair are observed in 15%
to 30% of patients (Table VII).265-267
Multiple reports have identified a strong relationship
between outcomes following AAA repair and both hos-
pital and individual surgeon case volume and experi-
ence.101,259,262,268,269 For example, Birkmeyer and col-
leagues,268 using national Medicare claims data and the
Nationwide Inpatient Sample 1994-1999, found a 7.8%
mortality rate following elective AAA repair in very low
(17/year) volume hospitals versus 4.4% in very high
(79/year) volume hospitals. Dimick et al270 reviewed
3,912 patients undergoing AAA repair in 1997 and noted a
4.2% overall in-hospital mortality. Mortality was 3% at high
volume hospitals, in contrast to 5.5% at low volume hospi-
tals. Surgeon specific volume and specialized training have
also been observed to be of significance. Dimick et al270
found that lowest perioperative AAA mortality was associ-
ated with operations performed by vascular surgeons
(2.2%), compared with cardiac surgeons (4.0%) and general
surgeons (5.5%) (P .001). In risk-adjusted analysis, high-
volume hospital, vascular surgery specialty, and high–
volume surgeon were all independently associated with
lower risk of in-hospital operative mortality. Risk reduc-
tion was 30% for high-volume hospitals and 40% for
operation by a high-volume surgeon. AAA repair by
general surgeons compared with vascular surgeons was
associated with 76% greater risk of death.270 Similar
training and specialty-related outcome relationships
were noted by Cronenwett and Birkmeyer in the Dart-
mouth Atlas of Healthcare.271 The overall 30-day mor-
tality rate for open AAA repair in 1996 was 5.5%, but
ranged from 4% to 7.9% among surgeons performing
more than 10 per year and those performing fewer than
four per year. Mortality was 4.4% for vascular surgeons,
5.4% for cardiothoracic surgeons, and 7.3% for general
surgeons. We recommend that OSR is best performed at
centers that have a documented in-hospital mortality of
less than 5% for elective repair.
Elective OSR for AAA should be performed at centers with a
documented in-hospital mortality of less than 5% for open repair of
infrarenal AAA.
Level of recommendation: Strong
Quality of evidence: High
Endovascular repair
Endovascular aortic aneurysm repair (EVAR) has rap-
idly expanded since Parodi’s first report272 and is progres-
sively replacingOSR for the treatment of infrarenal abdom-
inal aortic aneurysms (AAAs).273 According to nationwide
hospital databases, there has been a 600% increase in the
annual number of EVAR procedures performed in theUnited States since 2000.266 Although long-term durabil-
ity and associated costs have not been completely estab-
lished, EVAR now accounts for more than half of all AAA
repairs. Moreover, since the introduction of EVAR, the
annual number of deaths from intact and ruptured AAA has
significantly decreased in the United States. This has coin-
cided with an increase in elective AAA repair after the
introduction of EVAR and a decrease in the diagnosis and
repair of ruptured AAA.274
Infrarenal fixation. EVAR usually requires adequate
nonaneurysmal proximal and distal attachment sites. Prox-
imal fixation may be obtained through infrarenal or supra-
renal fixation. According to the instructions for use of
endografts with infrarenal fixation, an infrarenal neck at
least 15mm in length and less than 32mm in diameter with
an angulation 60° is required for optimal sealing. Pooled
results from EVAR devices included in the published Life-
line report (ie, Guidant AnCure [Indianapolis, Ind],
Medtronic AneuRx [Santa Rosa, Calif], Gore Excluder
[Flagstaff, Ariz], and Endologix PowerLink [Irvine, Calif],
provide safety and efficacy data for endografts with infrare-
nal fixation.275,276 The number of EVAR devices with
infrarenal fixation submitted for FDA review ranged from
121 for Ancure to 416 for AneuRx. The pooled results as
well as device-specific data obtained from FDA websites
indicates that 30-day mortality rates with these devices
ranged from 1% with Gore Excluder to 4.2% for the
Guidant Ancure endograft. Major complications or adverse
events within 30 days were not provided in the Lifeline
report but ranged from 13.6% in FDA reports with
the Gore Excluder to 35.6% with Guidant Ancure.277 In
device-specific published studies, early ruptures were only
reported for the AneuRx device and were 0.3%.278 Primary
conversion ranged from 0% for the Excluder device up to
9.7% for the Ancure system. The overall incidence of Type
I endoleaks within 30 days following EVAR with en-
dografts with infrarenal fixation was 4.2% and ranged from
0.9% to 11%.279
Suprarenal fixation. Suprarenal fixation has been
proposed as a more effective means of proximal fixation
when the morphologic features of the proximal neck are
unfavorable, including, short length, severe angulation,
reverse taper, a barrel-shaped neck, circumferential mural
thrombosis, or calcification. Despite the potential advan-
tages of suprarenal fixation, concerns have been raised
regarding the short- and long-term risks of renal or mesen-
teric artery embolization and occlusion. To date, several
observational studies have reported the efficacy and safety
of suprarenal endograft fixation.280-284 Moreover, almost
50% and 87% of endografts used in the DREAM and
EVAR-1 trials, respectively, were performed with en-
dografts that used suprarenal fixation. Significantly, rates of
renal dysfunction appear to be equivalent for endografts
with transrenal nitinol or stainless steel stents and not
significantly different among patients undergoing EVAR
with infrarenal or suprarenal fixation.283 Although supra-
renal fixation may produce a higher incidence of small renal
infarcts, in most patients these do appear to be clinically
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with suprarenal fixation appears to be multifactorial and
transient in most patients.285 Nonetheless, renal artery
occlusion and infarctions have been reported in patients
with preexisting renal artery occlusive disease286,287 and,
while infrequent, visceral dysfunction and celiac or mesen-
tery artery occlusion may occur secondary to suprarenal
fixation.288,289
Recommended management of the internal iliac
artery. Exclusion of the hypogastric artery (HA) to pre-
vent a type II endoleak is usually required during endovas-
cular repair of aortoiliac aneurysms that involve either the
distal common iliac artery or the hypogastric artery it-
self.290-294 Embolization of the hypogastric artery increases
by 16% the proportion of AAAs suitable for EVAR. Several
observational studies have revealed that unilateral emboli-
zation of the hypogastric artery can be performed during
EVAR with minimal adverse events.291,292 Although but-
tock claudication and erectile dysfunction occur in up to
40% of patients after unilateral hypogastric artery emboli-
zation, these symptoms tend to improve over time.295
Indeed, one of the largest series of patients undergoing HA
interruption during AAA repair revealed that persistent
buttock claudication developed in 12% of unilateral and
11% of bilateral hypogastric artery interruptions, whereas
impotence occurred in 9% of unilateral and 13% of bilateral
HA occlusions.296 Despite concerns about prolonged pro-
cedural time and increased amount of contrast, concomi-
tant unilateral HA embolization during EVAR has been
shown to be safe and effective, as compared with staged
procedures.297
Bilateral hypogastric artery occlusion with endograft
extension into both external iliac arteries is occasionally
required in high-risk patients when there is no distal fixa-
tion zone in either common iliac artery or the aneurysm
involves both common iliac and hypogastric arteries. Al-
though antegrade flow into at least one of the hypogastric
arteries should be attempted, if possible, bilateral HA em-
bolization may be necessary in some situations. Initial
concerns about life-threatening pelvic or colonic ischemia
and neurologic deficits after bilateral hypogastric artery
interruption during EVARmay have been overestimated as
several recent reports suggest that such devastating compli-
cations rarely occur.224,291,298,299 The risks associated with
bilateral HA occlusion are restricted to a more severe,
persistent and frequent buttock claudication and erectile
dysfunction.
Technical considerations that may reduce the incidence
of adverse events when bilateral HA embolization is re-
quired, include staging bilateral HA embolization when
possible, embolization of the main trunk of the HA so as
to preserve pelvic collateral vessels, preserving collateral
branches from the common and deep femoral and external
iliac arteries, and maintaining adequate anticoagulation
during these procedures.291,299
Alternative strategies to avoid bilateral HA occlusion
during EVAR include open or endovascular revasculariza-
tion of at least one HA by transposition or bypass graftingor endografting from the external iliac artery.300,301 More
recently, iliac branched endografts designed to preserve
flow to theHA have been used with satisfactory preliminary
results.302-304 Combining two bifurcated endografts has
also be reported.305 Long-term durability of iliac branched
devices is not well defined, although a recent study has
reported 87% patency at 60 months.304 At this time,
branched endografts are not commercially available in the
United States.
As an adjunct to EVAR, bilateral hypogastric artery occlusion may
be acceptable in certain anatomic situations for patients at high-
risk for OSR.
Level of recommendation: Strong
Quality of evidence: Moderate
Role of EVAR in patients requiring urgent or emer-
gent repair. In an effort to improve outcomes for patients
presenting with symptomatic or ruptured AAAs, the impact
of urgent or emergent EVAR has been recently evaluated.
A randomized trial comparing EVAR and OSR for rup-
tured AAAs revealed that the suitability for endovascular
repair was 46%, but the application rate was lower
(30%).306 Observational studies have revealed improved
outcomes after emergent EVAR for ruptured AAAs, but
significant selection bias and lack of uniform inclusion
criteria and reporting standards confounds these analy-
ses.307-312 In contrast, a recent industry-sponsored study of
emergent EVAR and OSR in 100 consecutive patients
across 10 institutions in Europe failed to demonstrate
improved in-hospital (35% and 39%, respectively) or
3-month mortality (40% and 42%).313 Open repair was
performed in 80% of cases because of unfavorable neck
anatomy. Identical mortality rates (53%) were also reported
in a study of 32 patients randomized to EVAR or OSR.314
Nonetheless, recent studies analyzing national trends in the
United States have observed that endovascular repair is
being used with increasing frequency in the emergency
management of ruptured AAA, with decreasing mortal-
ity.315,316 Results in non-teaching centers and low volume
institutions, however were substantially worse than those in
teaching hospitals and high volume centers and fewer women
who present with ruptured AAA are treated by EVAR.316
Establishing a protocol for urgent or emergent EVAR
for ruptured AAAs appears to be essential to obtain optimal
results.309 Such protocols require that emergency depart-
ment personnel alert the vascular team and operating room
staff as soon as a ruptured AAA is suspected and a CT
angiogram is obtained in hemodynamically stable patients.
All other patients should be directly transferred to the
operating room. “Hypotensive hemostasis,” which refers
to restricting aggresive fluid resuscitation as long as the
patient remains conscious and systolic blood pressure ex-
ceeds 50 mmHg to 70 mmHg, should be implemented to
limit hemorrhage.312 The question of whether to use an
aortic occlusion balloon remains unresolved with some
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others recommend its use in the presence of hemodynamic
instability or anatomic limitations that prevent expeditious
EVAR.317 A femoral artery approach with use of a long
sheath may be more expeditious than use of brachial artery
access. The sheath may be advanced into the supraceliac
aorta to support the balloon and permit its removal after
endograft placement.317 In hemodynamically unstable pa-
tients that do not have a preoperative CT scan, device
selection and evaluation of the proximal and distal en-
dograft sealing zones can be based on intraoperative an-
giography, and ideally, on intravascular ultrasound. Both
bifurcated and aortouniliac endografts have been used for
emergent EVAR of ruptured AAAs.309-311
Abdominal compartment syndrome is a well-recognized
complication after EVAR for ruptured AAAs.309,311,318 It typi-
cally occurs among hemodynamically unstable patients in
which a large retroperitoneal hematoma and diffuse visceral
edema results in intra-abdominal hypertension and multi-
ple system organ dysfunction. Early recognition through
measurement of bladder pressure and surgical decompres-
sion are necessary to improve survival. Use of an aortic
occlusion balloon, coagulopathy, massive transfusion, and
conversion to an aortouniliac device, are predictors of
abdominal compartment syndrome.318 Although colonic
ischemia is less frequent after EVAR, it remains an acknowl-
edged risk, particularly among patients who have under-
gone repair of a ruptured AAA.319,320 Regardless, of the
type of repair, the mortality rate in the presence of colonic
ischemia is approximately 50%.
Emergent EVAR should be considered for treatment of a ruptured
AAA, if anatomically feasible.
Level of recommendation: Strong
Quality of evidence: Moderate
Role of EVAR in high-risk and unfit patients for
open repair. Several observational studies have reported
excellent technical success and low rates of morbidity and
mortality after EVAR in high-risk patients with significant
co-morbidities.1,321-324 However, the EVAR-2 trial found
no survival advantage for patients deemed medically unfit
for OSR when randomized between elective EVAR or no
intervention.325 Substantial in-hospital (9%) and pre-
procedural (8%) mortality was observed in the group ran-
domized to EVAR, which persisted when urgent or emer-
gent EVAR cases were excluded from the analysis (30-day
mortality 7%). Several limitations of this study have been
noted. First, nine ruptures and 14 deaths occurred in the
EVAR group (n  166) prior to elective repair with a
median time from randomization to EVAR of 57 days.
Second, 47 patient crossovers occurred from the no inter-
vention group (n  172) to EVAR. Finally, inclusion
criteria were subjective with the potential for introduction
of bias by the treating surgeon.75 In summary, a number of
reports have documented that EVAR can be performed
with low rates of perioperative mortality and morbidity inpatients at high risk for OSR. Nonetheless, the ability of
EVAR to provide a survival advantage for patients consid-
ered truly unfit for open repair is uncertain. Although a
number of preoperative risk prediction methods have been
reported,326 additional research is needed to define objec-
tive criteria that identify patients who are unfit for OSR and
whose anticipated life expectancy limits benefit from
EVAR.
EVAR may be considered for high-risk patients unfit for surgical
repair.
Level of recommendation: Weak
Quality of evidence: Low
Perioperative outcomes of elective EVAR
Incidence of 30-day and in-hospital mortality. It
would seem to be axiomatic that EVAR, as a minimally
invasive technology would be associated with lower in-
hospital and 30-day mortality rates as compared to OSR.
Indeed, among nonrandomized but controlled trials, 30-
day mortality rates of less than 2% were reported among all
FDA pivotal study populations (AneuRx [n  416] 1.7%;277
Excluder [n  235] 1.3%;327 Zenith [n  352] 1.1%;328,329
Powerlink [n  192] 1%330). However, pooled trial data
representing the OSR cohorts was associated with a com-
parable 30-day mortality rate of 1.4%.277 In an analysis of
pooled trial data for patients considered at high risk for
OSR, 30-day mortality for patients treated by EVAR or
OSR was comparable (2.9% EVAR vs 5.1% OSR, P 
.32).321 Among randomized, prospective trials, lower mor-
tality was observed among those patients treated by EVAR.
Specifically, in-hospital mortality rates in the EVAR-1 trial
and the DREAM trial were 1.7% and 1.2% for EVAR and
6% and 4.6% for OSR, respectively.36,331 These differences,
however, did not achieve statistical significance (P  .1).
Moreover, only 23% of screened patients in the EVAR-1
trial were eligible for randomization with more than half of
all patients excluded from the trial due to the presence of
anatomic unsuitability for EVAR (54%).
It is noteworthy that with rapid adoption of this tech-
nology in the United States, much lower mortality rates
have been reported for EVAR in analyses of large state-
wide and multi-state population-based databases.277 These
trends were noted early after initial FDA approval of first
generation devices. In-hospital mortality of 4.2% for OSR
and 0.8% for EVAR was observed among approximately
1,600 patients treated in New York State treated in 2002.33
Lee at al265 analyzed 4,607 patients who underwent OSR
and 2,565 treated by EVAR that were enrolled in the
Nationwide Inpatient Sample (NIS) database in 2002.
In-hospital mortality was significantly lower following
EVAR (1.3% vs 3.8%), despite the presence of greater
cardiovascular co-morbidity. In a review of 65,502 patients
entered into the NIS database who underwent elective
EVAR between 2001 and 2004, Timaran et al324 noted an
in-hospital mortality of 2.2%. Stratified analyses, including
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mortality was 1.7% in patients with the most severe comor-
bidities and 0.4% among those with lower comorbidity. In
this regard, analysis of a high risk cohort from the Veteran
Affairs (VA) National Surgical Quality Improvement Pro-
gram (NSQIP) revealed those patients who underwent
elective EVAR (n  788) had a significantly lower 30-day
mortality than those treated by OSR (n  1,580) (3.4% vs
5.2%, P .047).322 In a recent analysis of 45,000 propensity-
score-matched Medicare beneficiaries treated by EVAR
and OSR, mortality was significantly lower after EVAR
(1.2% vs 4.8%; P  .001), with reduction in mortality
most pronounced for those of advanced age (80 to 84
years: 1.6% vs 7.2%;  85 years: 2.7% vs 11.2%; P 
.001).34 While a variety of demographic features and
clinic data were used for propensity matching, it is
possible that differences in outcome reflect the inclusion
of anatomically more complex aneurysms among the
cohort treated by OSR. Nonetheless, the marked differ-
ence in outcome among octagenarians is consistent with
the anticipated physiologic benefits of a minimally inva-
sive intervention, particularly among patients at high risk
for perioperative morbidity and mortality. It is notewor-
thy that disparities in EVAR outcome have been identi-
fied between patients of varying ethnicity and insurance
type332
Procedural outcomes and primary conversion to
OSR. Procedural blood loss is less for EVAR (414 mL,
range, 96 mL to 783 mL) when compared to OSR (1,329
mL, range, 451 mL to 1,800 mL),277 with reductions in
ICU (0.7 vs 1.6 d) and hospital (4.2 days vs 9.9 days)
stays.277 In the initial experience with EVAR, early conver-
sion to OSR was necessary in as many as 18% of pa-
tients.333,334 In both the DREAM and EVAR-1 trials,
primary conversion to open repair occurred in 1.8% of
patients,36,331 while in recent FDA pivotal trials, conver-
sion ranged from 0% (Excluder and Zenith) to 1.6% (End-
ologix).277 In the recent analysis of 45,000 propensity-
score-matched Medicare beneficiaries treated between
2001 and 2004, Schermerhorn et al reported conversion to
OSR at initial EVAR in 1.6%.34 Thirty-day technical suc-
cess, in which EVAR leads to complete exclusion of the
AAA with or without prior secondary intervention, has
ranged from 77% to 100% with a mean of 91% in eight
studies (n  1,493).277
Major medical adverse events. Major medical com-
plications are lower after EVAR than OSR. A meta-analysis
of observational studies conducted prior to 2002 demon-
strated an incidence of systemic complications of 9% after
EVAR, as compared with 22% after OSR, largely attribut-
able to fewer cardiac and pulmonary events.335 Major
adverse events within 30 days of treatment ranged from
13.6% for Excluder and 18.8% for Powerlink to an inci-
dence of adverse events of 24.4% for the Zenith endograft
in controlled, non-randomized FDA sponsored pivotal
trials. The incidence of major adverse events were substan-
tially higher in the OSR cohorts (26% to 42.5%).277 Like-
wise, the DREAM trial reported fewer systemic com-plications after EVAR as compared withOSR (12% vs 27%),
although all cardiac morbidity (EVAR 5.3% vs OSR 5.7%)
and severe cardiac complications (EVAR 1.8% vs OST
1.1%) were comparable among groups.36 As noted earlier,
Anderson et al33 reported a lower incidence of cardiac
complications in a statewide review of patients treated by
EVAR in 2002 (3.3% vs 7.8%). A similar, though less
dramatic difference, in the incidence of perioperative MI
was reported by Schermerhorn et al (7% vs 9.4%, P 
.001).34 In addition, the latter study noted a reduction in
the incidence of pneumonia (9.3% vs 17.4%, P  .001),
acute renal failure (5.5% vs 10.9%, P .001), and need for
dialysis (0.4% vs 0.5%, P  .047) among those treated by
EVAR.34 Post-implantation syndrome, characterized by
fever, malaise, back or abdominal pain after EVAR, may last
up to 10 days, but appears to be a relatively rare phenom-
enon. It has been attributed to the release of cytokines after
aneurysm sac thrombosis.336 Contrast-induced nephropa-
thy occurs infrequently after EVAR.
Device related complications and 30-day re-
intervention. The incidence of local vascular or device
related complications, as well as the 30-day re-intervention
rate is greater after EVAR than OSR. The DREAM trial
demonstrated that a higher incidence of local vascular or
device related complications occurred after EVAR than
OSR (16% vs 9%).36 Similar findings have been reported in
several observational studies with local or vascular compli-
cations occuring in 9% to 16% of patients after EVAR.277
Moreover, a pooled analysis that included pivotal data from
the Ancure, AneuRx, Excluder, Powerlink, and Zenith
studies revealed a 30-day re-intervention rate of 15.6%.277
In the EVAR-1 and EVAR-2 trials, reintervention within
30 days of EVAR occurred in 9.8% and 18% of patients,
respectively.325,331 Groin and wound complications are the
most frequent event. Stents, endografts, or surgical repair
may be required if severe vascular access injuries occur.
Distal embolization is now rare with lower profile intro-
ducer systems. Limb occlusion occurs more frequently in
patients with aortoiliac occlusive disease, a small (14mm)
distal aorta and tortuous vessels and when unsupported
endografts are used. The EVAR-1 trial revealed that almost
75% more secondary interventions were undertaken within
30 days of the procedure or within the same admission after
EVAR as compared with OSR.331
Mid-term outcomes. The DREAM and EVAR-1 tri-
als have provided mid-term follow-up data at two and four
years, respectively.337,338 Although a 3% reduction in
aneurysm-related mortality persisted throughout the
follow-up period, in both trials, the initial reduction in
all-cause mortality was eliminated within one to two years
with equivalent overall survival in both treatment groups.
Moreover, EVAR was associated with a greater number of
late complications and secondary reinterventions. In the
EVAR-1 trial, reinterventions occurred three times as of-
ten, exceeding 20% at four years, whereas for OSR the
reintervention rate was approximately 6%. The DREAM
trial showed a similar pattern in the first nine months after
randomization (hazard ratio, 2.9; 95% confidence interval
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tion for EVAR and OSR, thereafter (hazard ratio, 1.1; 95%
CI, 0.1 to 9.3). A population-based study of 45,660Medi-
care beneficiaries undergoing either EVAR or OSR dem-
onstrates similar findings.34 Survival curves converged
three years after initial repair and by four years, AAA
rupture (1.8% vs 0.5%) and AAA-related reinterventions
(9.0% vs 1.7%) were more likely after EVAR than after
OSR. In contrast, laparotomy-related complications that
required surgical repair were more likely among patients
who had undergone OSR (9.7%, vs 4.1%), as were hospi-
talizations for bowel obstruction or abdominal-wall hernia.
Although the DREAM trial reported that quality of
life scores were greater for those patients treated by
EVAR, within six months, differences were no longer
apparent and sexual function scores were similar or bet-
ter for those patients who underwent OSR.338 Likewise,
in the EVAR-1 trial, SF-36 mental component scores
were similar for both treatment groups throughout the
postoperative and follow-up periods, with differences
only observed for the physical component scores, which
were lower during the first three postoperative months
for those treated by OSR.337
In summary, the recognized benefits of EVAR, including
reducedmorbidity, ICU and hospital length of stay, as well as
observed lower perioperativemortality rates, especially among
elderly patients, has led to widespread adoption of this tech-
nology.Nonetheless, it is recommended that elective EVAR is
best performed at centers that have a documented in-hospital
mortality of less than 3% and a primary conversion rate toOSR
of less than 2% for elective repair. Further research is needed to
improve EVAR devices and related techniques to reduce
complications and long-term follow-up; to identify whether
EVAR outcomes vary with respect to endograft type or aneu-
rysm features; and to define the relationship of hospital and
physician volume to outcomes after EVAR.
EVAR should be performed at centers with documented in-hospital
mortality for elective EVAR of less than 3% and a perioperative
conversion rate to OSR of less than 2%.
Level of recommendation: Strong
Quality of evidence: High
Management of associated vascular disease in pa-
tients undergoing OSR or EVAR. Coexistence of other
vascular disease with an abdominal aortic aneurysm is com-
mon. Several series reporting observations of aortography
have documented greater than 50% stenosis in 20% to 40%
of renal arteries, 10% to 15% of celiac or SMA branches, and
20% to 30% of iliac vessels.339,340 Whether or not to extend
repair to include correction of such associated vascular
disease remains uncertain.
Decision making for intervention is based upon a con-
sideration of (1) the severity of associated lesions, (2) the
presumed natural history of the disease, and (3) the antic-
ipated morbidity and mortality risk of combined repair.
While definitive long-term natural history data are not
available for many associated lesions, some data is availablein regard to renal artery stenosis. Tollefson et al evaluated
sequential arteriographic findings in patients with renal
artery stenosis undergoing aortograms for evaluation of
aortic disease.341 Progression of renal stenosis was noted in
53% of these patients over a mean follow-up of 4.5 years,
with 9% of arteries progressing to total occlusion. All vessels
that occluded had severe (75%) pre-existant stenoses.
Zierler and co-workers prospectively determined progres-
sion of renal artery stenosis with serial ultrasound duplex
scans.342 These investigators observed progression in 42%
of renal artery lesions by two years, with progression to total
occlusion in approximately 5% per year for arteries with
60% stenosis.
In terms of mesenteric occlusive disease, Thomas and
colleagues examined 980 consecutive aortograms over a
six-year period to identify patients with significant mesen-
teric stenosis but without symptoms of mesenteric isch-
emia. During subsequent follow-up, these authors noted
that 27% of patients with significant three-vessel visceral
artery disease developed clinically overt symptoms of mes-
enteric ischemia.343
Because of such data, it is often reasoned that concom-
itant repair of associated disease would be prudent in order
to avoid the technical difficulty and potential risk of later
reoperation should this prove necessary due to progression
of the associated vascular lesions. While simultaneous aortic
grafting and renal artery reconstruction have been reported
in some series to have a negligible impact on the risk of
death or major complications,344-348 many other reports
clearly document significantly increased morbidity and
mortality risk of combined operation.349-351
From available data, it can be concluded that prophy-
lactic repair of associated renal or mesenteric artery disease
cannot be justified.352 A decision to repair each lesion
should be based upon its own individual merits and indica-
tions. When associated renal or mesenteric disease is severe
and symptomatic, combined operation employing either
bypass grafting or endarterectomy techniques in conjunc-
tion with aortic graft repair may well be appropriate, and is
generally associated with good long-term functional out-
comes. However, increased risks secondary to the more
extensive procedure must be recognized.
An alternative strategy in the current era of increasing
endovascular interventions is staged treatment of the associ-
ated vascular disease, employing catheter-based techniques for
treatment of renal or visceral artery disease before AAA repair.
While this may be an appealing and useful solution in many
patients, especially high-risk individuals, definitive data as to
the timing of renal or visceral angioplasty, as well as early and
long-term risks and merits of such an approach are not cur-
rently available.
Accessory renal arteries are present in 15% to 20% of
patients, and occasionally arise from the aneurysm it-
self.339 Whether or not such accessory vessels require
preservation and reimplantation into the graft at the time
of open aneurysm repair remains uncertain. However,
several recommendations should be considered. First, it
is important to identify the presence of such arteries prior
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or ligation during operative dissection. Accessory renal
arteries of a clinically significant size are detected in the
majority of preoperative CT scans. Secondly, it may be
possible to determine how much of the involved kidney
is supplied by this branch. Preservation and reimplanta-
tion, similar to an IMA Carrel patch, may be considered
for a sizable (3 mm) accessory renal artery or those that
supply one third or more of the renal parenchyma.
Obviously, the presence of preoperative renal insuffi-
ciency makes sacrifice of any renal parenchyma and func-
tion less appealing.
Such recommendations have come into question
with increasing use of EVAR. Since preservation of ac-
cessory renal arteries arising from the segment of aneu-
rysmal disease being excluded is obviously not possible
with this methodology, the frequency with which acces-
sory renal arteries have been sacrificed has increased.
Most reported experience in this regard has concluded
that loss of such accessory renal branches has rarely led to
any clinically significant sequelae, such as deterioration
of renal function, development of postoperative hyper-
tension, or symptomatic renal infarcts.353,354 This sug-
gests that preservation and reimplantation during OSR
may not be as important as previously believed.
Concomitant surgical treatment of other vascular disease at the
time of open AAA repair should be considered in selected patients.
Level of recommendation: Strong
Quality of evidence: Moderate
Preoperative renal artery or superior mesenteric angioplasty and
stenting is recommended for selected patients with symptomatic
disease.
Level of recommendation: Strong
Quality of evidence: Low
Preservation of accessory renal arteries that are 3 mm or larger in
diameter or supply more than one-third of the renal parenchyma
can be beneficial at the time of open aneurysm repair.
Level of recommendation: Strong
Quality of evidence: Low
Laparoscopic aneurysm repair
Several observational studies, case reports, and technical
notes have reported that totally laparoscopic or laparoscopic-
assisted repair of AAAs is feasible.355-360 Most of these
reports, however, originate in a few specialized centers with
extensive experience in laparoscopic techniques. Because of
the advanced technical skills and specialized instrumenta-
tion necessary for these procedures, laparoscopic repair of
AAAs has not been widely adopted.
The surgical principles of laparoscopic AAA repair are
the same as those of OSR (ie, endoaneurysmorrhaphy,
aneurysm exclusion and anatomic reconstruction). In the-
ory, the main advantage of laparoscopic AAA repair is the
performance of the standard surgical repair using a lessinvasive approach, which potentially may result in less mor-
bidity and excellent long-term results compared to conven-
tional AAA repair. Moreover, laparoscopic AAA repair
could also be used in patients with AAAs unsuitable for
EVAR. Further evaluation of this technique is required to
define its role in the treatment of elective AAAs.
Although laparoscopic-assisted AAA repair has been
used for several years, totally laparoscopic repairs using
transperitoneal and retroperitoneal approaches have only
recently been reported.355,358,360 Inflammatory and rup-
tured AAAs are considered contraindications for totally
laparoscopic repair. Robotically assisted laparoscopic repair
has also been described, although it appears that further
refinements are necessary to reduce operative and aortic
cross-clamping times.361
Prior experience with laparoscopic aortic reconstructions
for aortoiliac occlusive disease is considered essential before
performing total laparoscopic AAA repair. The learning curve
is steep and about 50 procedures are considered necessary to
obtain a good level of expertise.358 Despite the technical
challenges of laparoscopic AAA repair, postoperative compli-
cations and mortality appeared not to be affected by the
technique itself. The main technical difficulties are the expo-
sure of the abdominal aorta, as the small intestine limits the
operative field, and the performance of laparoscopic anasto-
mosis.358 Hand-assisted laparoscopic aneurysm repair can be
performed safely with operating times similar to those of
OSR.362 This technique has distinct advantages over a total
laparoscopic approach as it can be applied tomost repairs with
fewer procedures required to gain proficiency.
Similar perioperative mortality rates have been reported
for laparoscopic and standard open repairs, although mor-
tality may decrease with experience.358 Operative and
clamp times are usually longer than those reported for
open AAA repair. However, these times can be signifi-
cantly reduced as individual experience is gained. Blood
loss is comparable to that of OSR, although back bleed-
ing from lumbar arteries requires intense suction and
may collapse the abdominal cavity with immediate loss of
visualization. Postoperative systemic, local, and vascular
complications are similar for both laparoscopic and open
repairs.357 Postoperative ileus, return to normal diet,
ambulation, and need for analgesics appeared to be
reduced after laparoscopic repair compared with OSR.
Lengths of ICU and hospital stay, however, are not
significantly different.
The benefit of totally laparoscopic or laparoscopic-assisted AAA
repair as compared with open repair is uncertain.
Level of recommendation: Weak
Quality of evidence: Low
Cost and economic considerations in aneurysm repair
Costs of AAA repair are substantial, and vary considerably
based on complexity of the repair, patient co-morbidities,
length of stay, incidence of complications, and overall
outcome. These costs include those associated with pre-
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ning, operative materials and procedures, post-procedural
recovery, lost productivity, and outpatient follow-up, as
well as late secondary interventions required to maintain
aortic integrity.363 The majority of data from both out-
come case series and decision modeling analysis identify
EVAR procedural costs as being higher than those associ-
ated with OSR in the elective setting. Jonk and associ-
ates364 reviewed all EVAR and OSR cost and cost compar-
ison studies published through 2005 and noted that
devices alone accounted for between 34% and 78% of total
EVAR hospitalization expense, consistently the largest sin-
gle item for such procedures. Given reduced procedural
morbidity associated with EVAR, cost-effectiveness follow-
ing the initial period of hospitalization might be expected
to favor EVAR. However, in the EVAR-1 trial,337 device-
related secondary events and re-interventions accounted
for a 33% increase in cost at four years. Retrospective case
series data also demonstrate cost disparities between EVAR
and OSR.365 Nonetheless, Tarride et al366 recently found
that EVAR was cost-effective compared to OSR in a one-
year prospective observational study of high-risk patients
treated in a single payor health care system. All three
Markov modeling studies published to date have also pre-
dicted higher lifetime costs associated with EVAR.364 In the
most recent analysis using data incorporated from the
EVAR-1 and DREAM trials, a cost effectiveness ratio of
£110,000/QALY was calculated for a 70-year-old man un-
dergoing EVAR for a 5.5 cm AAA as compared with OSR;
a result incompatible with the notion of overall cost-
effectiveness. In this analysis, EVAR consistently produced an
incremental cost-benefit ratio of  £30,000/QALY over a
range of alternative cost and outcome scenarios.367
Previous analyses have suggested that cost effective-
ness determinations for elective and urgent procedures
should be calculated independently. Visser et al368 eval-
uated the in-hospital and one-year follow-up costs of
EVAR and OSR in patients with hemodynamically sta-
ble, acute symptomatic or ruptured AAA treated be-
tween 2001 and 2005. Total in-hospital costs and total
overall costs, including one-year follow-up costs, were
lower in patients who underwent EVAR. ICU admission
and length of stay, primarily related to the incidence of
complications, represented the single most important
cost differential between EVAR and OSR.
In summary, given the evolutionary nature of EVAR
devices, procedures, perceived procedural imperatives, as
well as postoperative surveillance technologies and pro-
tocols, additional studies are required to identify ap-
proaches that improve cost effective care for patients
with AAA. In the process of conducting these studies, we
recommend that more comprehensive analytic strategies
be employed to capture all costs associated with aneu-
rysm repair, including societal costs associated with time
away from work for patients and family members provid-
ing care. Moreover, detailed and disease-specific quality
of life instruments should be developed, validated, and
employed.ANESTHETIC CONSIDERATIONS AND
PERIOPERATIVE MANAGEMENT
Choice of anesthetic technique and agent
OSR. Except in unusual circumstances, open aneu-
rysm repair requires general anesthesia, because of the
required relaxation of the abdominal wall musculature.369
Low doses of relaxing agents, such as a benzodiazepine plus
an opiate, are recommended followed by conventional
inhalation agent-based general endotracheal anesthesia. In-
sertion of monitoring lines prior to induction of anesthesia
is appropriate if such monitoring devices improve the safety
of induction.
Infusion of an analgesic through an epidural cathe-
ter, by controlling pain fiber input, appears to lower the
required dose of general anesthetic agents and may be
associated with a shorter time to extubation.370 How-
ever, infection and bleeding risks along with the poten-
tial for delayed surgery in the event of a “bloody tap”
may outweigh these benefits. Successful elective OSR
using “mini-laparotomy” or by retroperitoneal exposure
has been performed using epidural anesthesia with either
low dose inhalation anesthesia or in the awake pa-
tient.371-373 These techniques should be considered
experimental.
EVAR. EVAR can be safely performed under general,
epidural, or local anesthesia. Data from the EUROSTAR
registry suggests lesser degrees of anesthesia may be of
benefit.374 From 1997 to 2004, 3,848 patients underwent
EVAR using general anesthesia, 1,399 using epidural anes-
thesia, and 310 using local anesthesia. Local anesthesia was
associated with shorter operative times, reduced ICU ad-
mission, shorter hospital stay, and fewer systemic compli-
cations. Epidural anesthesia showed some advantages over
general anesthesia, but the effect was less dramatic. Several
small single-institution reports have shown similar re-
sults.375,376 Mortality differences have not been observed.
Ruptured AAA. OSR of a ruptured AAA will require
general endotracheal anesthesia, as the benefits of expedi-
tious total relaxation and pain control outweigh the risks
of intubation, placement of a high epidural catheter, or
administration of local anesthesia in an awake patient in
significant pain. However, vasodilation on induction will
often lead to sudden hypotension and the surgical team
should consider prepping and draping the surgical field
or placing a transbrachial or transfemoral balloon for
thoracic aortic control prior to induction. Treatment of a
ruptured AAA by EVAR may be performed under local
anesthesia, if pain related to rupture can be appropriately
controlled.
Open aneurysm repair should be performed in most patients under
general endotracheal anesthesia.
Level of recommendation: Strong
Quality of evidence: High
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Level of recommendation: Weak
Quality of evidence: Low
Use of epidural and local anesthetic techniques along with conscious
sedation is suggested for patients undergoing EVAR.
Level of recommendation: Weak
Level of evidence: Low
Antibiotic prophylaxis
Prophylactic treatment with systemic antibiotics, ad-
ministered immediately preoperatively, reduces the risk of
wound infection and almost certainly early graft infection
among all forms of arterial reconstructive surgery by be-
tween three-quarters and two-thirds, respectively.377 Stew-
art et al377 reviewed 10 studies that randomised 1297
patients to receive either prophylactic antibiotic or placebo.
Significantly, three studies demonstrated that antibiotic
prophylaxis for more than 24 hours was without added
benefit. No evidence existed of a significant advantage
among comparable regimens of first or second-generation
cephalosporins, penicillin/-lactamase inhibitor, amino-
glycosides, or vancomycin.
Intravenous administration of a first generation cephalosporin or,
in the case of a history of penicillin allergy, vancomycin, is
recommended within 30 minutes prior to skin incision. Prophylactic
antibiotics should be continued for no more than 24 hours.
Level of recommendation: Strong
Quality of evidence: High
Intraoperative fluid resuscitation and blood
conservation
Preoperative autologous blood donation avoids disease
transmission and transfusion reactions, but is dependent on
accurate labeling, storage, and retrieval. In addition, eryth-
ropoesis may be stimulated by this practice, but the mag-
nitude of this benefit is unclear. Limitations include re-
stricted use to elective surgery, limited volume of blood
donation, increased clerical demands and expense, as well as
waste of non-utilized donated blood.378
Intraoperative blood salvage duringOSR can be achieved
using either red blood cells (RBC) processors or hemofiltra-
tion devices and are attractive under conditions where the
safety of banked blood is a concern.379 Cell processors collect
shed whole blood and wash and separate RBC by centrifuga-
tion. The resulting product is pure, with anaphylaxis, toxins,
and other waste products removed with a high degree of
efficiency. However, platelets and clotting factors are lost. In
contrast, hemofiltration devices filter shed whole blood, such
that water and some waste products are removed. The result-
ing whole blood reinfusion containsmore clotting factors and
cellular components, but at the cost of potential contami-
nants. While advantages should exist for RBC-salvage and
ultrafiltration devices in the presence of potential contamina-tion or coagulopathy, respectively, this has not beenborne out
clinically. After CABG, hemoglobin values were higher
after direct RBC infusion and platelet counts higher after
ultrafiltration, but coagulation parameters, blood loss,
and outcomes were similar.380 Likewise, cell salvage
techniques during vascular surgery have not prevented
the need for transfusion and have not proven cost-
effective.381 In a Cochrane review, cell salvage tech-
niques reduced the need for RBC transfusion by 0.67
units per patient, but did not alter clinical outcome.382
Routine use of cell salvage and ultrafiltration devices
cannot be recommended, but is recommended if large
blood loss is anticipated or disease transmission from
banked blood likely. This is an area where further inves-
tigation is needed, particularly with regard to empiric
benefits of different techniques and cost-benefit analysis.
The benefit of maintaining a hemoglobin of at least 10
gm/dL during OSR is unknown and randomized trials have
not been conducted to address this question. It would seem
prudent to have a lower threshold for transfusion in the
presence of ongoing blood loss, but evidence is lacking.383
Optimal blood replacement therapy during complexOSR has
not been defined and research in this area is encouraged. In
the trauma population, plasma and packed RBCs in equal
proportions, plasma, packed RBCs, and platelets in a 1:1:1
ratio, and warm fresh whole blood instead of component
therapy have all been advocated.384-386 It is recommended
that transfusion be considered during OSR if blood loss is
ongoing or expected and the hematocrit is less than 30%.
Blood product-based resuscitation strategies are preferred with
liberal use of platelets, plasma, and perhaps fresh whole blood.
Intraoperative blood salvage during OSRIntravenous
fluids for abdominal aortic surgery has been the topic of
many investigations over the past three decades, however,
there is no overwhelming evidence in favor of the preferen-
tial use of any specific type of fluid or fluid regimen.387
Moreover, there is no evidence of the beneficial effects of
combination fluid therapy, with colloid and crystalloid.
Although the cost of fluid is small, a positive fluid balance
after OSR may be predictive of major adverse events, in-
creased ICU and overall hospital length of stay.388
Preoperative autologous blood donation may be beneficial for
patients undergoing open aneurysm repair.
Level of recommendation: Weak
Quality of evidence: Moderate
Cell salvage or an ultrafiltration device is recommended if large
blood loss is anticipated or the risk of disease transmission from
banked blood considered high.
Level of recommendation: Strong
Quality of evidence: Weak
Intraoperative blood transfusion is recommended for a hematocrit
30% in the presence of ongoing blood loss.
Level of recommendation: Strong
Quality of evidence: Weak
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resuscitation fluids should consider use of FFP and platelets in a
ratio with packed blood cells of 1:1:1.
Level of recommendation: Strong
Quality of evidence: Weak
Intra- and postoperative cardiovascular monitoring
Clinical studies have not demonstrated altered out-
come from routine use of either a pulmonary artery cathe-
ter, transesophageal echocardiography, ST-segment mo-
nitoring, or intravenous nitroglycerin. Pulmonary artery
catheters have been used since the 1980s to measure car-
diac output and index, outflow resistance, and central ve-
nous and pulmonary artery pressure, and estimate contrac-
tility. They are moderately invasive, though safe when used
correctly. However, multiple randomized trials have shown
no significant benefit when used routinely in non-selected
patients.389-391 In one randomized study, central venous
pressure (CVP) measurements were found to be just as
helpful as formal pulmonary artery catheterization.390 Pe-
ripherally placed central catheters (PICCs) have been
shown to correlate with conventional CVP measurements
in aortic surgery.392 However, PICC lines are inadequate
for high volume infusion of fluid. The risks, logistics, and
expense of routine transesophageal echocardiography
(TEE) during open AAA repair exceed the benefits. How-
ever, in an unstable patient TEE can be used to estimate
volume status, stroke volume, and cardiac output,393 and
can identify tamponade or valvular dysfunction.394
Early postoperativeMI (40%)most often occurs suddenly
without a warning period of ischemia, presumably due to
rupture of a vulnerable plaque. Delayed MI (60%), occurring
24 to 72 hours postoperatively, typically is preceded by a
period of electrically and chemically detectable myocardial
ischemia, and probably related to prolonged stress.63 This
suggests that early identification of myocardial ischemia may
reduce the risk of MI, by identifying the need for aggressive
control of heart rate and attention to analgesia, oxygenation,
and volume status.63 Improved strategies to identify postop-
erative patients at risk for MI are needed and is an area
recommended for further study. Moreover, little is known
about the ability of intervention at the time of identification of
myocardial injury to alter clinical outcomes.
Currently, troponinmeasurement is recommended for all
patients with postoperative ECG changes, chest pain, or other
signs of cardiovascular dysfunction, since troponin elevation is
predictive of adverse short- and long-term outcomes.395-397
Conventional ECG monitoring uses five leads, of which only
one is precordial and most often placed at V5. In a study of
185 consecutive patients undergoing vascular procedures, full
12-lead ECGs with computerized ST-segment analysis and
routine troponin measurements for up to 72 hours postoper-
atively showed transient myocardial ischemia in 21% of pa-
tients and MI in 6.5%. Leads placed at V3 and V4 were most
predictive and the combination of two precordial leads led to
greater than 95% sensitivity when compared to troponin lev-
els.398 A similar study showed abnormal troponin levels in14% and MI in 5% of patients following aortic surgery.63
Patients at increased risk of a cardiac event following EVARor
OSR should be considered forECGmonitoring andmeasure-
ment of postoperative troponin levels.
Pulmonary artery catheters should not be used routinely in aortic
surgery, unless there is a high risk for a major hemodynamic
disturbance.
Level of recommendation: Strong
Quality of evidence: High
Central venous access is recommended for all patients undergoing
open aneurysm repair.
Level of recommendation: Strong
Quality of evidence: High
Intraoperative and postoperative ST-segment monitoring is
recommended for all patients undergoing open aneurysm repair,
but required in only selected patients undergoing EVAR.
Level of recommendation: Strong
Quality of evidence: Moderate
Transesophageal echocardiography can be beneficial in determining
the cause of an intraoperative hemodynamic disturbance.
Level of recommendation: Weak
Quality of evidence: Moderate
Postoperative troponin measurement is recommended for all
patients with ECG changes or chest pain after EVAR or OSR.
Levels of recommendation: Strong
Quality of evidence: High
Maintenance of body temperature
Maintenance of body temperature during aneurysm
repair is beneficial. In one trial randomizing patients to two
methods of warming, patients who were hypothermic
(36 °C) on arrival to the post-anesthesia care unit
(PACU) had lower cardiac output and platelet counts,
higher prothrombin times and APACHE II scores, and a
greater incidence of sinus tachycardia and ventricular ar-
rythmias.399 Forced air warming blankets have been shown
to be beneficial400 when compared with circulating water
mattresses alone.399 Warmed inhaled gasses401 and infused
liquids402 have also been shown to be of benefit. The
benefit of forced air-warming blankets applied to the lower
extremities, as opposed to the upper trunk, during pro-
longed aortic clamping is unknown.
Core body temperature should be maintained at or above 36 °C
throughout OSR or EVAR.
Levels of recommendation: Strong
Quality of evidence: High
The role of the ICU
Typically, all patients are admitted to an ICU setting
following OSR, while most patients undergoing EVAR
are not. Although distinctions are increasingly blurred,
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more intensive monitoring, differs from a non-ICU set-
ting in that it allows ventilatory support, arterial and
venous pressure monitoring, and infusion of cardio- and
vasoactive drugs. Thus, there is an unavoidably greater
cost.403 Some patients probably do not need ICU sup-
port even after OSR. One recent study showed that the
majority of such patients could be managed without ICU
admission, although “overnight intensive recovery” in
the postoperative care unit was provided.404 Another
group reported selective ICU admission after four hours
of observation in the PACU for patients eligible for “fast
track” OSR. Although mean ICU stay in 30 patients was
0.87 0.10 days, the percentage of patients sent directly
to the floor was not reported.405 In a second report from
a large academic practice, selective use of the ICU fol-
lowing OSR was achieved in 56% of patients. While
length of stay decreased, mortality and morbidity were
not different.406
Postoperative ICU care can be useful for patients undergoing open
aneurysm repair and in selected patients undergoing EVAR.
Level of recommendation: Strong
Quality of evidence: Moderate
Postoperative nasogastric decompression and
perioperative nutrition
Open aneurysm repair involves laparotomy or a large
retroperitoneal exposure and in either case the viscera are
either extensively mobilized or firmly retracted. Thus,
many clinicians routinely use nasogastric (NG) drainage for
several days postoperatively. This practice, however, may be
unnecessary and perhaps even detrimental. In a random-
ized trial, 80 patients undergoing OSR had their NG tube
removed at extubation or left until flatus. No difference in
outcome was observed, and only three of 40 patients with-
out initial placement of a NG tube required insertion.407 In
a more recent study, a higher incidence of respiratory
complications was noted among patients with nasogastric
suction.408
Preoperative malnutrition adversely affects outcome after
surgery.However, perioperative total parenteral nutrition is of
benefit only if support is continued for several weeks. Patients
undergoing elective EVARwould not be expected to have an
ileus or require NG decompression.
Nasogastric decompression should be used intraoperatively for all
patients undergoing open aneurysm repair, but in only selected
patients postoperatively.
Level of recommendation: Strong
Quality of evidence: Moderate
Elective open aneurysm repair should not be performed unless
nutritional status is optimized.
Level of recommendation: Strong
Quality of evidence: HighParenteral nutrition is recommended if a patient is unable to
tolerate enteral support seven days after OSR or EVAR.
Level of recommendation: Strong
Quality of evidence: High
Perioperative pain management
Guidelines for acute pain management published by
the American Society of Anesthesiologists report similar
efficacy of patient controlled anesthesia (PCA) as compared
with nurse or other staff-administered intravenous (IV)
analgesia.409 Overall patient satisfaction with PCA is high.
In order to avoid inadequate analgesia after a period of
sleep or unconsciousness, continuous low dose infusion of
an analgesic has been incorporated into most PCA proto-
cols. Postoperative epidural anesthesia also provides excel-
lent pain relief. A Cochrane review reports a meta-analysis
of 13 randomized trials involving 1,224 patients having
abdominal aortic surgery, 597 of whom were treated using
epidural delivery and 627 using systemic opiates. Those
receiving epidural anesthesia had significantly fewer overall
cardiovascular complications, myocardial infarction, respi-
ratory failure, gastrointestinal complications, and renal in-
sufficiency. Patients spent 20% less time intubated and
reported less subjective pain, especially with movement. A
thoracic epidural approach appeared to yield better out-
comes than lumbar. No mortality differences were no-
ted.410 These potential benefits are associated with in-
creased costs, which in one study of 80 patients averaged
$2,489 for those treated with epidural anesthesia versus
$443 for those treated with IV PCA.411 In addition, pa-
tients on antiplatelet or anticoagulant therapy may be at
increased risk of epidural hematoma.412
Epidural anesthetic or intravenous PCA are recommended for
postoperative pain control after OSR.
Level of recommendation Strong
Quality of evidence High
Intramuscular delivery of opiates is not recommended for ongoing
analgesia following aortic surgery.
Level of recommendation: Strong
Quality of evidence: Moderate
Perioperative prophylaxis for deep vein thrombosis
It has been assumed that the risk of deep vein throm-
bosis (DVT) in patients undergoing vascular surgery with
systemic heparinization is low.413 However, DVT after
open AAA repair appears to be underappreciated. In a series
of 50 consecutive patients undergoing OSR without pro-
phylaxis, postoperative venography revealed acute DVT in
21% of patients, nearly 80% of which involved the calf veins,
none of whom were symptomatic.414 A Cochrane analysis
of all non-randomized prospective studies in aortic surgery
identified an incidence of all DVT that ranged between 0%
and 20.5%, averaging 9.2%, among patients without DVT
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excluded. Although a reduced risk would be anticipated
after EVAR, the incidence of femoral or popliteal DVT
after endovascular repair was 6% among 50 patients exam-
ined by Duplex ultrasonography.413 Consistent with these
findings, deMaistre et al416 recently reported an incidence
of lower extremity DVT of 10.2% after OSR and 5.3% after
EVAR (P  .28), despite prophylaxis with thigh-length
compression bandages or stockings, early mobilization, and
daily subcutaneous injection of low-molecular-weight hep-
arin beginning in most patients within the first day after
OSR or EVAR. Symptomatic pulmonary embolism (PE)
occurred in 1.4% of patients after OSR, but most patients
identified with DVT were asymptomatic. There was a trend
toward delayed initiation of low dose heparin prophylaxis
among patients that developed aDVT (1.7 days vs 0.9 days,
P  .09). Indeed, aortic surgery may be associated with a
higher risk of DVT than infrainguinal bypass. Hollyoak et
al417 reported an incidence of DVT 41% after aortic surgery
compared with 18% after peripheral artery surgery among
patients who did not receive heparin prophylaxis. Among
patients receiving low dose subcutaneous heparin or
LMWH, Farkas et al418 reported that 8% of patients devel-
oped DVT after aortic surgery with an incidence of 3% after
distal bypass. Similarly, Fletcher et al419 noted an incidence
of DVT in 12% and 9% of patients receiving low dose
heparin prophylaxis after aortic surgery and lower extremity
bypass, respectively.
Overall, most patients undergoing EVAR or OSR can be
considered at moderate to high risk for DVT, given advanced
age, duration of surgery 45 min, and the increasing preva-
lence of obesity in the US population. Therefore, DVT pro-
phylaxis consisting of intermittent pneumatic compression
and early ambulation are recommended for all patients under-
goingOSRor EVAR. Patients at high risk (eg, prior history of
DVT/PE, obesity (BMI25), limitedmobility status,malig-
nancy, hypercoaguable state) should receive either lowmolec-
ular weight heparin (LMWH) (enoxaparin 40 mg SQ once a
day) or unfractionated heparin (5000 IU SQ two or three
times a day) initiatedwithin 24hours per the judgement of the
treating surgeon. If a high-risk patient has a history of renal
insufficiency, unfractionated heparin (5000 IU SQ twice a
day) is preferred, which is also favored for those patients who
have an epidural catheter. A detailed review of DVT and
methods to reduce risk after surgery has recently been pub-
lished.420
DVT prophylaxis consisting of intermittent pneumatic compression
and early ambulation are recommended for all patients
undergoing OSR or EVAR.
Level of recommendation: Strong
Quality of evidence: High
Low dose heparin prophylaxis should be considered for patients at
high risk for DVT undergoing aneurysm repair.
Level of recommendation: Strong
Quality of evidence: HighPOSTOPERATIVE AND LONG-TERM
MANAGEMENT
Late outcomes after open surgery and EVAR
Both EVAR and OSR are associated with late compli-
cations.19,257,421 Given the routine use of postoperative
imaging after EVAR, the incidence of complications has
been better documented than for OSR.19,257 Clinically
significant complications appear to occur more frequently
after EVAR, but this technology continues to evolve and
newer endografts are associated with a lower incidence of
migration, disconnection, and material fatigue. Nonetheless,
the incidence of certain procedure specific complications, such
as Type II endoleaks, remains unchanged.421,422
Long-term complications related to the incision. Ret-
roperitoneal incisions for AAA repair have been associated
with weakened lateral abdominal wall musculature and a
bulge in up to 15% of patients.195 The more commonly
used laparotomy for transperitoneal AAA repair is, how-
ever, associated with a higher incidence of late small bowel
obstruction, and approximately one in five patients may
develop a ventral hernia, a finding that appears to be
substantially more common after treatment of AAA than
aortic occlusive disease.423 Surgical exposure of the femoral
arteries is common to both EVAR and OSR. Postoperative
seromas and femoral nerve injury, manifest by anterior and
inner thigh paresthesias, are well documented but infre-
quent events. Percutaneous approaches for EVAR will
likely reduce these problems, but increase the risk of hema-
toma or pseudoaneurysm formation.
Para-anastomotic aneurysm. Para-anastomotic an-
eurysms after AAA repair include both false aneurysms
resulting from a disruption of the anastomosis and true
aneurysms that develop adjacent to the anastomosis. True
metachronous aneurysms reportedly occur at a 1.5 to
threefold greater frequency than anastomotic pseudoaneu-
rysms. However, the incidence of para-anastomotic aneu-
rysms is not clear, since few studies have systematically
followed patients after OSR with serial imaging. Predispos-
ing factors include hypertension, COPD, and tobacco
use.424-428 In the era prior to CT imaging, Szilagyi ana-
lyzed a 15-year experience with OSR in which anastomoses
in the femoral region were at highest risk (3%), followed by
the iliac (1.2%) and infrarenal aorta (0.2%).427 Subsequent
studies have reported an incidence of between 4% and 10%
at 10-year follow-up.425 In one study of 511 patients,
Kaplan-Meier analysis has shown a probability of a para-
anastomotic aneurysm of 0.8% at five years, 6.2% at 10
years, and 35.8% at 15 years.426 The likelihood that 15
years after OSR 20% to 40% of patients may have a para-
anastomotic aneurysm has been confirmed by others, espe-
cially among those patients treated with an aortobifemoral
graft.425,428 Indolent graft infection should be suspected in
all pseudoaneurysms.
Given the inability to precisely differentiate anasto-
motic disruption from degenerative aneurysmal dilatation,
indications for repairing para-anastomotic aneurysms are
not well defined. Clearly large size and rapid enlargement
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icant risk of major morbidity and mortality. Thus, the
successful application of endovascular repair when anatom-
ically appropriate has been a welcome approach to this
difficult problem.429,430
Graft infection. All implanted prostheses, whether
placed by OSR or EVAR, are at risk for infection either at
implantation or later by hematogenous seeding. This com-
plication is rare and represents about 0.3% of all aortic
operations.431 Graft infection, however, is the indication
for intervention in up to 25% of redo aortic surgery.432
Although controversial, the risk of graft infection after
EVAR may be lower than OSR, perhaps due to delivery
of the endoprosthesis through a completely enclosed
system or decreased dissection around the viscera. The
EUROSTAR registry reported only three procedures for
endograft infection in almost 3000 patients followed up to
five years; a rate of 0.1%.421 The EVAR-1 trial, however,
showed a comparable incidence between OSR and EVAR
over a four year follow-up period.337 Similarly, in a recent
analysis of more than 45,000 Medicare beneficiaries, graft
infection or fistula at four years was 0.2% among patients
treated by EVAR and 0.3% for those who underwent OSR
(P  .13).34 Likeiwse, in a review of 14,000 patients
undergoing AAA repair inWashington State, Vogel et al433
reported a nearly identical two-year incidence of graft in-
fection of less than 0.2% among those treated with OSR or
EVAR. Graft infection after EVAR or OSR may present in
isolation or in association with a fistula to a neighboring
viscus, most commonly the duodenum.434,435
Primary aortic graft infection usually presents late, on
the average three years after implantation and on occasion
much later.432 Femoral extension of the abdominal grafts
increases the incidence of graft infection from 1% to nearly
3%, as determined by an 18-year review of 664 patients
treated by OSR.436 Other predisposing factors include
surgical revision and emergency surgery. Presentations can
be quite diverse including generalized sepsis, groin puru-
lence and drainage, pseudoaneurysm formation, or ill de-
fined pain.437 Staphylococcal organisms are the most fre-
quent bacterial isolates. Although the diagnosis may be
obvious, CT scanning usually provides the most informa-
tion about the nature of the problem, extent of infection,
and other associated abnormalities. Angiography may be
required to plan therapy, especially if the infection involves
the femoral region precluding use of the common femoral
artery as an outflow for the reconstruction.
Treatment traditionally includes excision of all infected
graft material with extra-anatomic reconstruction, particu-
larly in the presence of extensive contamination. Outcome
of treatment is poor with elevated mortality and limb
loss.432,438-442 Rupture of the infected aortic stump after
aortic closure does occur and is almost always uniformly
fatal. Many treatment strategies have been explored with
various degree of success. Reilly demonstrated improved
survival after staging the procedure, starting with the extra-
anatomic reconstruction and, in a separate procedure, per-
forming the excision and debridement of the infectedfield.441 In-situ reconstruction using femoral vein, silver or
antibiotic impregnated grafts, or arterial homografts, have
all been advocated as surgical options that may be associ-
ated with reduced overall mortality in selected patients with
limited contamination.438,443-447
Aortoenteric fistula (AEF) can complicate a graft
infection in 1% to 2% of patients.434,437 Although the
duodenum is most frequently affected, all viscera, in-
cluding small and large bowel, have been implic-
ated.435,437 A commonpresentation is upper gastrointestinal
(UGI) bleeding.448 Herald bleeds may ultimately progress
to an exsanguinating hemorrhage, if the source of the
bleeding is not identified and treated promptly. All patients
with a previous aortic graft and an UGI bleed should be
suspected of having an AEF. The diagnosis of AEF is one of
exclusion and is occasionally confirmed by endoscopy or
CT scanning.449-451 Bleeding presentations are more com-
mon when the anastomosis erodes into the GI tract, while
sepsis and abscess formation may be more common with
para-prosthetic fistula involving the body of the graft. Treat-
ment strategies are similar to primary graft infections butmust
include closure of the visceral tear and on rare occasion diver-
sion of the GI tract. Anastomotic erosionmay be less contam-
inated than the paraprosthetic presentation andmore suitable
for in-situ replacement. Separation of the graft from the vis-
cera, which is desirable at the original operation, is necessary
during the repair of an AEF.452
Antibiotic prophylaxis of graft infection is required prior to
bronchoscopy, gastrointestinal or genitourinary endoscopy, and any
dental procedure that may lead to bleeding.
Level of recommendation: Strong
Quality of evidence: High
Generalized sepsis, groin drainage, pseudoaneurysm formation, or
ill-defined pain after OSR or EVAR should prompt evaluation of
graft infection.
Level of recommendation: Strong
Quality of evidence: High
GI bleeding after OSR or EVAR should prompt evaluation of an
aortoenteric fistula.
Level of recommendation: Strong
Quality of evidence: High
Excision of all graft material along with aortic stump closure with
an omental flap and extra-anatomic reconstruction is
recommended for treatment of an infected graft in the presence of
extensive contamination.
Level of recommendation: Strong
Quality of evidence: High
In situ reconstruction with deep femoro-popliteal vein after graft
excision and debridement is a recommended option when
contamination is limited.
Level of recommendation: Strong
Quality of evidence: High
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arterial homografts, or a PTFE graft may be considered in patients
with an infected prosthesis and limited contamination.
Level of recommendation: Weak
Quality of evidence: Low
Limb occlusion. Nearly 25% of all arterial reinterven-
tions after OSR are due to limb occlusion, and are most
common in patients with associated occlusive disease.432
Limb occlusion appears to be greater in women and in
grafts extending to the femoral artery. Isolated limb occlu-
sion usually presents with claudication, but occlusion of the
entire graft may present with severe ischemia. On occasion,
the patient presents before complete occlusion of the graft.
Endografts are at a higher risk for limb thrombosis than
prostheses placed during the course of OSR, as observed in
the EVAR-1 trial.337 Endograft limbs can be narrowed by a
calcified small diameter aortic bifurcation or tortuous, an-
gulated, and diseased iliac arteries. Non-supported limbs, as
was the case with the Ancure endograft, were at high risk of
limb occlusion and required frequent stenting.453 How-
ever, even stented limbs may occlude due to infolding,
kinking between stents, or by the abutting the arterial wall
in tortuous iliacs.421 Stenotic limbs, occasionally noted by
Duplex examination or as a result of a reduction in ankle-
brachial index or new onset of claudication, can be success-
fully treated by additional stenting.
Treatment of an occluded limb after EVAR or OSR
includes, thrombectomy or lytic therapy with secondary
endovascular or local surgical intervention, or extra-
anatomic bypass, such as femoral-femoral or axillo-femoral
bypass. Standard mechanical balloon thrombectomy is less
likely to be successful with EVAR grafts because of sharp
edges produced by stents and concerns related to dislodg-
ing or disrupting the sealing zones.
Follow-up of patients after EVAR or open surgery should include a
thorough lower extremity pulse exam or ABI.
Level of recommendation: Strong
Quality of evidence: High
New onset of lower extremity claudication, ischemia, or a reduction
in ABI after OSR or EVAR should prompt an evaluation of graft
limb occlusion.
Level of recommendation: Strong
Quality of evidence: High
Endoleak. Endoleak, or persistent blood flow in the
aneurysm sac outside of the endograft, is the most frequent
complication after EVAR and has been reported in nearly
one in four patients at some time during follow-
up.421,454,455 It is one of the most common abnormalities
identified on late imaging and used to justify lifelong follow-
up of these patients. Diagnosis of endoleak is most com-
monly performed by CT imaging, although Duplex imag-
ing can be effective.456,457 An endoleak can connect an
inflow source with an outflow vessel resulting in elevatedsystemic pressures in the sac. When an outflow path does
not exist, diastolic pressure in the sac is higher than the
systemic pressure and the net effect is a higher mean pres-
sure in the sac.458 Four types of endoleak have been de-
scribed, independent of graft type:459,460
Type I endoleakoccurs in the absence or loss of complete
sealing at the proximal (Type IA) or distal (Type IB) end of
the stent graft. Type I endoleak is associated with significant
pressure elevation in the sac and has been linked to a contin-
ued risk of rupture.461-463 Incidence of Type I endoleak
increases with difficult anatomic situations, such as short or
angulated necks, and landing zones with calcification, tortu-
osity, or uneven size. Every attempt should bemade to resolve
Type I endoleaks noted at the time of EVAR before the
patient leaves the intervention suite. On occasion, small per-
sistent Type I endoleaks may be observed and if endovascular
intervention has been unsuccessful, the only alternative is
surgical conversion. Somemay seal spontaneously by the time
of the first postoperative surveillance study.
Proximal Type IA endoleaks can respond to expansion
with less compliant balloons, extension if any additional
landing zone exists, or placement of a balloon expandable
stent.22 If none of these maneuvers work, obliteration of
the luminal crease with coils, glue or other embolic agents
may be effective.464,465 Distal Type I endoleak are usually
treated by distal extension. Should a Type I endoleak
persist, conversion to OSR is appropriate, especially in
patients with large aneurysms who can undergo OSR.466
Type II endoleaks are the most common form of
endoleak and arise from retrograde filling of the sac by
lumbar branches or the inferior mesenteric ar-
tery.422,454,455 Detection of a Type II endoleak may be
difficult if the endoleak is associated with low flow. For
those detected at the time of EVAR, further treatment is
not indicated, since spontaneous resolution is possi-
ble.461,464,465,467 When noted at follow-up, many re-
solve spontaneously, but some may persist. Endoleaks
arising from the inferior mesenteric artery are thought to
resolve less frequently than those from lumbar vessels and
may be associated with a greater risk of sac expansion.468
Although delayed AAA rupture secondary to a Type
II endoleak has been reported, it is rare and many
patients with Type II endoleaks are observed without
treatment. Some patients will show some sac shrinkage,
an indication of low pressure in the aneurysm sac. The
majority will show no change in sac size and require
continued surveillance. A risk benefit analysis of close
follow-up versus early intervention should take into con-
sideration the age of the patient, size of the aneurysm,
the vessels involved, and the expected efficacy of treat-
ment. A definite subset of patients with Type II leaks will
demonstrate sac enlargement, an indication of elevated
pressure, and increased risk of rupture. Treatment of
these Type II endoleaks is recommended.23,469,470
Obliteration of Type II endoleaks can be difficult.
Transarterial retrograde catheterization of the offending
branches with occlusion by coiling or other embolic agents
can be effective, but requires advanced endovascular skills.465
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utilized successfully.458 The principle of treatment is to elim-
inate the branches at their junction with the aneurysm. Lapa-
roscopic ligation of the inferior mesenteric artery or lumbar
arteries is a third option for treatment of a type II endoleak.471
Type III endoleaks arise from poorly seated modular con-
nections or from disconnection and separation of components.
Less often it is the result of fabric erosion related to material
fatigue. Sac pressure can exceed arterial pressure. All Type III
endoleaks should be treated, typically with limb components, as
they represent a lack of exclusionof the aneurysmwith repressur-
ization of the aneurysm sac.461,462,472
Type IV endoleaks represents self-limiting blood seep-
age through the graftmaterial due to porosity and treatment is
not required. Typically, this form of endoleak is only noted at
the time of repair on post-implantation intra-operative an-
giography. An endoleak noted on follow-up imaging should
not be considered a Type IV endoleak.
Type I endoleaks should be treated.
Level of recommendation: Strong
Quality of evidence: High
Treatment is recommended for Type II endoleaks associated with
AAA expansion.
Level of recommendation: Strong
Quality of evidence: Moderate
Treatment may be considered for Type II endoleaks not associated
with AAA enlargement.
Level of recommendation: Strong
Quality of evidence: Moderate
Type III endoleaks should be treated.
Level of recommendation: Strong
Quality of evidence: High
Type IV endoleaks do not require treatment.
Level of recommendation: Strong
Quality of evidence: Moderate
Conversion to OSR of an AAA is recommended if a Type I or III
endoleak does not resolve with endovascular treatment.
Level of recommendation: Strong
Quality of evidence: High
Conversion to OSR of an AAA is recommended for a Type II
endoleak in association with a large or expanding aneurysm that
does not resolve with endovascular or laparoscopic treatment.
Level of recommendation: Strong
Quality of evidence: High
Endotension. An AAA may continue to enlarge after
endovascular repair, even in the absence of a detectable
endoleak, and this enlargement may lead to aneurysm
rupture. Explanations for persistent or recurrent pressuriza-
tion of an aneurysm sac include blood flow that is below thesensitivity limits for detection with current imaging tech-
nology or pressure transmission through thrombus or en-
dograft fabric.473,474 Additionally, a serous ultrafiltrate
across a microporous fabric can fill the aneurysm and in-
crease pressure.422,475 Since sources of endotension can be
difficult to detect, treatment strategies must be individual-
ized. Relining devices with low porosity alternatives may
abolish sac growth or induce shrinkage of the sac.476 On
occasion, explantation and conversion may be required
when no clear cause can be detected and endoleak, as a
cause of sac expansion, cannot be excluded.
Treatment of endotension to prevent aneurysm rupture is suggested
in selected patients with continued aneurysm expansion.
Level of recommendation: Weak
Quality of evidence: Low
Device migration. Device migration after EVAR is
multi-factorial and can be asymptomatic. It is normally de-
tected on CT scan by the presence of a Type I endoleak and
can lead to repressurization of the aneurysm sac and rupture.
Although cranialmigration of distal iliac attachment can occur
andmay have a similar effect in pressurizing the aneurysm sac,
the most common form is caudal migration of the proximal
aortic neck attachment site. The incidence of devicemigration
is influenced by its definition (5mmor 10mm) and technique
used tomeasure displacement.477,478 In this regard, the use of
three-dimensional CT reconstruction of thin slices (3 mm)
using a center-line of flow methodology provides the most
accurate measurements.
Device migration can occur intraoperatively or subse-
quent to device implantation. Intraoperative device migra-
tion of the proximal attachment component is usually
managed by the addition of a proximal aortic cuff. Most
concur that proximal attachment deployment should be
performed as close as possible to the inferior border of the
lowest renal artery. Appropriate magnification and angula-
tion of the C-arm provides optimal views of the landing
zones increases the reliability of deployment.
The incidence of postoperative device migration ap-
pears related to the duration of follow-up. Most series
evaluating device migration have reported increases after
24 months.273,478-480 Migration rates betwen 0% and 45%
have been reported in selected series with the largest mi-
gration rates reported after more than 24 months and with
devices that are no longer commercially available.479-481
Some of the anatomic factors that influence proximal at-
tachment device migration include: length of the aortic
neck (15 mm), shape of the aortic neck (conical vs.
straight), angulation of the aortic neck relative to center-
line (45°), presence of thrombus in the aortic neck,
excessive over sizing of the endografts (20%), and char-
acteristics of the device (suprarenal fixation, presence of
hooks or barbs, radial force alone).278,480,481
Component dislocation or disruption. Device integ-
rity was a major concern in a number of first generation
endografts (Stentor, Vanguard, and Challenger). The five
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have not demonstrated a significant problem with device
integrity in short and mid-term follow-up.329 Component
dislocation has been reported and it is usually related to either
insufficient overlap of the limb component in the main
body cage, decreased overlap of the limb in the iliac
artery or occasionally a combination of these factors.
Shrinking of the aneurysm sac, creating upward forces
can dislocate the distal iliac limb into the aneurysm sac
causing a Type I endoleak with sac pressurization and
potential rupture. It is recommended that the iliac limb
be extended at least two to three cm into the common
iliac artery and preferably down to the bifurcation. When
a proximal aortic cuff is necessary, sufficient overlap with
the main body is necessary to avoid component
separation.
Material fatigue, including metallic fracture, fabric fa-
tigue, and suture breakage, has been described as minor
(asymptomatic) or major (defined as material disruption asso-
ciated with deleterious outcomes such as endoleak and aneu-
rysm expansion and requires intervention). Jacobs et al evalu-
ated the role of material fatigue in a 10-year experience of 686
patients treated with EVAR and TEVAR,most of which were
cases of stent fractures in devices no longer available.482,483
The relationship of material fatigue to clinical outcome has
been reviewed both radiographically,484 and from careful
examination of explanted grafts.484,485 Zarins et al484 could
not identify a clear relationship between material fatigue and
adverse clinical outcome. Nearly all explanted grafts demon-
strated some type of material fatigue, including those ex-
planted at autopsy in patients whose cause of death was
unrelated to their aneurysm. Metallic fractures were found in
66%, fabric holes in 45%, and suture breaks in almost all
explanted grafts. However, in those patients with or without
fabric holes, there was no difference in rate of endoleak or
aneurysm enlargement. Interestingly, in explanted grafts with
metallic fracture, there was an increased rate of migration,
althoughmost structural abnormalities were remote from the
fixation site. Material fatigue was also noted in patients with
significant aortic angulation.
Recommendation for postoperative surveillance
The primary goal of AAA treatment is to prevent rup-
ture. As opposed to EVAR, OSR is not associated with a
risk of persistent sac enlargement, but may be associated
with late paranastomotic aneurysm formation or graft in-
fection. Although the later event is rare, late aneurysm
formation may be noted in approximately 1%, 5%, and 20%
of patients at five, 10, and 15 years after OSR, respecti-
vely.425,428 Thus, we recommend follow-up CT imaging at
five-year intervals after OSR.
EVAR using commercially available devices has been as-
sociated with a low rate of aneurysm related death. Five-year
results of FDA clinical trials involving three commercially
available devices (Excluder, Zenith, and AneuRx) demon-
strate freedom from aneurysm rupture of 100%, 96.8%, and
100%, respectively.329,422,486 Similar results have been re-
ported at 48 months for the Powerlink endograft.330 None-theless, late aneurysm rupture is a potential risk of all devices.
Therefore, continued surveillance after EVAR to detect aneu-
rysm growth, due to endoleak, device migration, or structural
failure is recommended. Protocols for EVAR surveillance
established as an outgrowth of initial FDA sponsored pivotal
trials consist of CT imaging at one, six, and 12 months after
initial repair and yearly thereafter.259,487 However, the fre-
quent use of CT scanning has raised concerns related to the
added costs of these studies, as well as cumulative radiation
exposure and potential lifetime cancer risk.488 Although ultra-
sound avoids radiation exposure and use of nephrotoxic con-
trast agents, concerns have been raised in the past regarding
the variable sensitivity of ultrasound in identifying en-
doleaks.456,489-491 Ashoke and collaborators456,492,493 in a
meta-analysis of 10 published studies comparing contrast en-
hanced CT with color Duplex ultrasonography (CDU),
found a sensitivity and specificity of 69% and91%, respectively,
with greater sensitivity in detecting Type I and III endoleaks
than Type II endoleaks. Recent studies, however, have sug-
gested that the lower sensitivity of CDU is offset by a high
degree of correlation between CDU and CT imaging in
detection of clinically significant endoleaks.493-496 Moreover,
recent small studies evaluating the role of contrast-enhanced
ultrasound in the detction of endoleaks report increased sen-
sitivity (97.5% vs 62.5%), negative predictive value (97.3% vs
65.1%), accuracy (89.3% vs 63.1%), and specificity (81.8% vs
63.6%) when compared with CDU.497-499 The utility of
ultrasound is primarily limited in obese patients or those
presentingwith substantial bowel gas or a large ventral hernia.
Based on these recent reports, some investigators have
suggested that follow-up with CDU as the sole imaging
modality is appropriate, if neither an endoleak nor AAA en-
largement is documented on the first annual CT scan.500 A
significant increase in aneurysm size or new onset of endoleak,
if detected by CDU at later follow-up, would prompt CT
imaging.501Eliminating the traditional sixmonthCT scanhas
also been recommended, if CT imaging one month after
EVAR does not identify an endoleak.500,502 Makaroun and
colleagues502,503 have reported that these protocols can be
instituted safely with minimal risk of an adverse clinical event.
Further research is needed to confirm the broader efficacy of
these modified protocols. It should also be noted that while
risk for endoleak declines as the number of negative postop-
erative scans increases, new endoleaksmay be identified as late
as seven years following EVAR.504 Convention has also dic-
tated that Type II endoleaks, in the absence of aneurysm
enlargement, should be followed with CT imaging at six-
month intervals. However, Type II endoleaks in the presence
of a shrinking or small stable aneurysm are characterized by a
relatively benign natural history in most cases.505 Thus, fur-
ther studies may demonstrate that CDU at six or even 12-
month intervals may be a reasonable alternative, especially for
patients whose aneurysms are less than 6.5 cm in diameter.470
In 2005, the FDA approved an AAA Pressure Man-
agement System. The sensor is implanted in the aneu-
rysm sac at the time of EVAR deployment and the APEX
trial confirmed that intrasac pressure and pressure
changes could be reliably measured.506 This system pro-
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by EVAR. As an alternative to postoperative CT imag-
ing, algorithms to identify a significant endoleak based
on pressure changes are under evaluation.
We currently recommend contrast enhanced CT imaging
one and 12 months during the first year after EVAR. Should
CT imaging at onemonth after EVAR identify an endoleak or
other abnormality of concern, postoperative imaging at six
months should be added to further evaluate the proper exclu-
sion of the aneurysm. If neither an endoleak nor aneurysm
enlargement is documented during first year after EVAR,
Color Duplex ultrasonography may be a reasonable alterna-
tive to CT imaging for postoperative surveillance. However,
these studies should be performed by a skilled technician in an
accredited non-invasive vascular laboratory. Likewise, fol-
low-upwithCDUandnon-contrastCT imaging is reasonable
for patients with renal insufficiency at any time after EVAR.
The presence of a Type II endoleak should initially prompt
continued CT surveillance to ascertain whether the aneurysm
is increasing in size. If the aneurysm is shrinking or stable in
size, follow-up with CDU may be a reasonable alternative to
continued CT imaging. Detection of a new endoleak after
prior imaging studies have suggested complete aneurysm sac
exclusion should prompt evaluation for a Type I or Type III
endoleak. Given the risk of paraanastomotic aneurysm, non-
contrast CT imaging at five-year intervals is recommended for
patients after OSR.
Surveillance during the first year after EVAR should consist of
contrast enhanced CT imaging at one and 12 months.
Level of recommendation: Strong
Quality of evidence: High
If a Type II endoleak or other abnormality of concern is observed on
contrast enhanced CT imaging at one-month after EVAR,
postoperative imaging at six months is recommended.
Level of recommendation: Strong
Quality of evidence: High
If neither endoleak nor AAA enlargement is documented during
first year after EVAR, Color Duplex ultrasonography is suggested
as an alternative to CT imaging for annual postoperative
surveillance.
Level of recommendation: Weak
Quality of evidence: Low
The presence of a Type II endoleak should initially prompt
continued CT surveillance to ascertain whether the aneurysm is
increasing in size. If the aneurysm is shrinking or stable in size,
follow-up with CDU is suggested as an alternative to continued CT
imaging.
Level of recommendation: Weak
Quality of evidence: Low
A new endoleak that is detected after prior imaging studies have
suggested complete aneurysm sac exclusion should prompt
evaluation for a Type I or Type III endoleak.
Level of recommendation: Strong
Quality of evidence: HighColor Duplex ultrasonography and a non-contrast CT scan are
recommended as a substitute for contrast enhanced CT imaging for
post-EVAR surveillance of patients with renal insufficiency.
Level of recommendation: Strong
Quality of evidence: High
Non-contrast CT imaging of the entire aorta is recommended at
five-year intervals after OSR or EVAR.
Level of recommendation: Strong
Quality of evidence: High
CARE OF THE PATIENT WITH AN AAA: AREAS
IN NEED OF FURTHER RESEARCH
A number of areas of uncertainty exist in the care of
patients with AAA that would benefit from further investi-
gation. While the following list is not meant to be compre-
hensive, future research efforts should consider addressing
the following topics:
● Improved strategies to identify patients at risk for
postoperative MI or cardiovascular related death.
● Perioperative management recommendations for pa-
tients with preexistent pulmonary disease.
● Perioperative management recommendations for pa-
tients with preexistent diabetes.
● Perioperative management recommendations for pa-
tients with renal insufficiency.
● Recommendations to reduce the risk of contrast-
induced nephropathy among patients with renal insuf-
ficiency undergoing EVAR.
● Optimal preoperative hydration regimen for patients
with renal insufficiency undergoing OSR.
● Perioperative management recommendations for pa-
tients with preexistent anemia.
● The genetic and molecular basis of familial AAA.
● Biomarkers and single nucleotide genetic polymor-
phisms that identify patients at risk for development,
progression, or rupture of an AAA.
● Applicability of estimates of AAA tensile stress and wall
strength or other CT, MRI, or PET derived parameters
to idemtify patients at risk for rapid growth or rupture.
● Screening for AAA in women and minorities.
● Optimal methods for invitation to AAA screening, ease
of access to initial ultrasound and follow up, costs and
workforce needs, and methods for providing risk-
benefit information to individuals offered screening.
● Psychological effects of screening on patients and their
partners.
● Effectiveness of screening programs initiated outside
of initial screening centers.
● Frequency of imaging surveillance for specific AAA
size groups (3 cm to 4.0 cm, 4.0 cm to 4.4 cm, 4.5 cm
to 4.9 cm, and 5.0 cm to 5.5 cm).
● Management recommendations for EVAR versus sur-
veillance and selective treatment for AAA 5.5 cm.
● Examination of the survival effect of immediate treat-
ment versus surveillance and selective treatment for spe-
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5.0 cm to 5.5 cm), age, gender, and fitness subgroups.
● Scales of fitness for surgical or endovascular interven-
tion.
● Management recommendations for EVAR versus no
intevention in high-risk patients unfit for OSR with an
AAA 5.5 cm.
● Improvement in medical management of patients with
large AAA considered unfit for OSR.
● Management recommendations for AAA in women
and minorities.
● Therapeutic strategies directed at reduction in AAA
growth rate or rupture risk, including clarification of
the potential role of doxycycline, roxithromycin, and
statin therapy in the progression of aneurysmal disease.
● Therapeutic strategies directed at regression of AAA
size.
● Biomarkers and genetic polymorphisms that identify
new avenues for pharmacotherapy.
● To identify whether OSR outcomes vary with respect
to aneurysm features, gender, ethnicity, or socioeco-
nomic status.
● Studies of hospital and physician volume-OSR out-
come relationship.
● Simulation training in OSR.
● Cost effectiveness strategies for OSR that include con-
siderations of time away from work for patients and
family members and disease-specific quality of life in-
struments.
● Recommendations for staged OSR and renal angio-
plasty or simultaneous OSR and renal artery bypass.
● Long-term safety of endografts with suprarenal fixa-
tion.
● Improvements in branched EVAR devices to maintain
pelvic perfusion.
● Effectiveness of EVAR for ruptured AAA.
● To identify whether EVAR outcomes vary with respect
to endograft type or aneurysm features.
● Studies of hospital and physician volume-EVAR out-
come relationship.
● Simulation training in EVAR.
● Cost effectiveness strategies for EVAR that include
considerations of time away fromwork for patients and
family members and disease-specific quality of life in-
struments.
● Recommendations for staged or simultaneous EVAR
and renal angioplasty.
● Improvements in laparoscopic approaches for AAA
repair.
● Simulation training in laparoscopic AAA repair.
● Recommendations for cell salvage and ultrafiltration
devices during OSR.
● Recommendations for intraoperative blood product-
based resuscitation during OSR.
● Recommendations for intraoperative fluid resuscita-
tion during OSR.
● Impact of of forced air-warming blanket position (ie,
lower extremities vs upper trunk) during OSR.● Optimal use of ICU after OSR.
● Benefits of DVT prophylaxis and optimal prophylactic
measures among patients undergoing OSR or EVAR.
● Improvements in EVAR devices and related techniques
to reduce complications and long-term follow-up.
● Strategies to reduce hernia formation and small bowel
obstruction after OSR.
● Infection-resistant aortic prostheses.
● Management strategies for Type II endoleaks.
● Durability of EVAR after additional interventions for
treatment of Type I or III endoleak or device migration.
● Postoperative surveillance protocols, including opti-
mal use of CDU, contrast enhanced CDU, and CT
imaging at various time periods after OSR or EVAR
(zero to five years, five to 10 years, 10 to 15 years).
● Effectiveness of pressure sensors in reduction of post-
operative surveillance costs.
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